Innate Pharma (IPHA) 6-K 15 Sep 22 2022 Q2 Innate Pharma Reports First Half 2022 Financial Results and Business Update Financial data

Cover

Cover	6 Months Ended
	Jun. 30, 2022
Cover [Abstract]
Document Type	6-K
Entity Registrant Name	Innate Pharma SA
Amendment Flag	false
Document Period End Date	Jun. 30, 2022
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q2
Entity Central Index Key	0001598599
Current Fiscal Year End Date	--12-31

Interim Condensed Consolidated

Interim Condensed Consolidated Statements of Financial Position - EUR (€) € in Thousands	Jun. 30, 2022	Dec. 31, 2021
Current assets
Cash and cash equivalents	€ 102,949	€ 103,756
Short-term investments	20,401	16,080
Trade receivables and others	48,447	18,420
Total current assets	171,797	138,256
Non-current assets
Intangible assets	43,260	44,192
Property and equipment	9,556	10,174
Non-current financial assets	34,806	39,878
Other non-current assets	149	148
Trade receivables and others - non-current	13,084	29,821
Deferred tax asset	7,778	5,028
Total non-current assets	108,633	129,241
Total assets	280,430	267,496
Current liabilities
Trade payables and others	18,667	28,573
Collaboration liabilities – current portion	14,167	7,418
Financial liabilities – current portion	30,851	30,748
Deferred revenue – current portion	9,094	12,500
Provisions - current portion	782	647
Total current liabilities	73,561	79,886
Non-current liabilities
Collaboration liabilities – non-current portion	58,954	32,997
Financial liabilities – non-current portion	12,523	13,503
Defined benefit obligations	2,696	2,975
Deferred revenue – non-current portion	8,333	25,413
Provisions - non-current portion	253	253
Deferred tax liabilities	7,778	5,028
Total non-current liabilities	90,537	80,169
Shareholders’ equity
Share capital	3,988	3,978
Share premium	377,998	375,220
Retained earnings	(272,241)	(219,404)
Other reserves	284	456
Net income (loss)	6,303	(52,809)
Total shareholders’ equity	116,333	107,440
Total liabilities and shareholders’ equity	€ 280,430	€ 267,496

Interim Condensed Consolidate_2

Interim Condensed Consolidated Statements of Income (Loss) - EUR (€) € in Thousands	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	[1]
Profit (loss) [abstract]
Revenue from collaboration and licensing agreements	€ 41,271	€ 8,304
Government financing for research expenditures	4,319	6,368
Lumoxiti Sales	0	0
Revenue and other income	45,589	14,671
Research and development expenses	(24,956)	(21,208)
General and administrative expenses	(12,140)	(12,643)
Operating expenses	(37,096)	(33,851)
Operating income (loss)	8,494	(19,179)
Financial income	4,048	3,490
Financial expenses	(6,166)	(1,781)
Net financial income (loss)	(2,118)	1,709
Net income (loss) before tax	6,376	(17,470)
Income tax expense	0	0
Net income (loss) from continuing operations	6,376	(17,470)
Net income (loss) from discontinued operations	(73)	(6,249)
Net income (loss)	€ 6,303	€ (23,719)
Weighted average number of shares, basic (in shares)	79,753,657	78,997,954
Weighted average number of shares, diluted (in shares)	79,753,657	78,997,954
Net income (loss) per share :
Basic income (loss) per share (in EUR per share)	€ 0.08	€ (0.30)
Diluted income (loss) per share (in EUR per share)	0.08	(0.30)
Basic income (loss) per share from continuing operations (in EUR per share)	0.08	(0.22)
Diluted income (loss) per share from continuing operations (in EUR per share)	0.08	(0.22)
Basic income (loss) per share from discontinued operations (in EUR per share)	0	(0.08)
Diluted income (loss) per share from discontinued operations (in EUR per share)	€ 0	€ (0.08)
[1]Comparative relating to the six months ended June 30, 2021 have been restated to reflect the impact of the classification of Lumoxiti's activities as discontinued operations in 2021. See note 17 of the interim condensed consolidated financial statements as of June 30, 2022.

Interim Condensed Consolidate_3

Interim Condensed Consolidated Statements of Comprehensive Income (Loss) - EUR (€) € in Thousands	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Statement of comprehensive income [abstract]
Net income (loss) for the period	€ 6,303	€ (23,719)	[1]
Items which will not reclassified in the consolidated statement of income (loss)
Actuarial gains and (losses) related to defined benefit obligations	471	566
Elements which will be reclassified in the consolidated statement of income (loss)
Foreign currency translation gain (loss)	(670)	(178)
Other comprehensive income (loss)	(199)	388
Total comprehensive (loss)	€ 6,104	€ (23,331)
[1]Comparative relating to the six months ended June 30, 2021 have been restated to reflect the impact of the classification of Lumoxiti's activities as discontinued operations in 2021. See note 17 of the interim condensed consolidated financial statements as of June 30, 2022.

Interim Condensed Consolidate_4

Interim Condensed Consolidated Statements of Cash Flows - EUR (€) € in Thousands	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Cash flows from (used in) operating activities [abstract]
Net income (loss)	€ 6,303	€ (23,719)	[1]
Reconciliation of the net income (loss) and the cash generated from (used for) the operating activities
Depreciation and amortization, net	2,030	2,168
Employee benefits costs	192	268
Change in provision for charges	134	4,952
Share-based compensation expense	2,596	853
Change in valuation allowance on financial assets	2,255	(1,031)
Gains (losses) on financial assets	(1,333)	(443)
Change in valuation allowance on financial instruments	(100)	(170)
Gains on assets and other financial assets	(25)	(86)
Interest paid	194	160
Other profit or loss items with no cash effect	(52)	(1,476)
Operating cash flow before change in working capital	12,194	(18,524)
Change in working capital	(10,976)	(12,638)
Net cash generated from / (used in) operating activities:	1,218	(31,162)
Cash flows from (used in) investing activities [abstract]
Acquisition of intangible assets, net	0	(33)
Acquisition of property and equipment, net	(420)	(240)
Purchase of non-current financial instruments	0	0
Disposal of property and equipment	0	2
Purchase of other assets	(1)	(63)
Interest received on financial assets	25	86
Net cash generated from / (used in) investing activities:	(395)	(247)
Cash flows from (used in) financing activities [abstract]
Proceeds from the exercise / subscription of equity instruments	192	61
Repayment of borrowings	(958)	(1,127)
Net interest paid	(194)	(160)
Net cash generated / (used in) from financing activities:	(960)	(1,226)
Effect of the exchange rate changes	(670)	(178)
Net increase / (decrease) in cash and cash equivalents:	(807)	(32,812)
Cash and cash equivalents at the beginning of the year:	103,756	136,792
Cash and cash equivalents at the end of the six-months period:	102,949	103,980
Summary of changes in working capital [abstract]
Trade receivables and others (excluding rebates related to capital expenditures)	61,531	45,121
Trade receivables and others (excluding rebates related to capital expenditures), variance	(13,290)	6,514
Deferred revenue - current and non-current portion	(17,427)	(38,066)
Deferred revenue - current and non-current portion, variance	(20,486)	(5,907)
Trade payables and others (excluding payables related to capital expenditures)	(18,667)	(17,026)
Trade payables and others (excluding payables related to capital expenditures), variance	(9,906)	(12,492)
Collaboration liabilities - current and non-current portion	(73,121)	(45,934)
Collaboration liabilities - current and non-current portion, variance	32,706	(752)
Total change in working capital	(47,684)	(55,905)
Total change in working capital, variance	€ (10,976)	€ (12,638)
[1]Comparative relating to the six months ended June 30, 2021 have been restated to reflect the impact of the classification of Lumoxiti's activities as discontinued operations in 2021. See note 17 of the interim condensed consolidated financial statements as of June 30, 2022.

Interim Consolidated Statement

Interim Consolidated Statement of Changes in Shareholders’ Equity - EUR (€)	Total		Share capital	Share premium	Retained earnings	Other reserves	Net income (loss)	Ordinary Shares Share capital	Preferred Shares Share capital
Balance at beginning of period (in shares) at Dec. 31, 2020								78,986,490	14,462
Balance at beginning of period at Dec. 31, 2020	€ 155,976,000		€ 3,950,000	€ 372,131,000	€ (156,476,000)	€ 355,000	€ (63,984,000)
Net income (loss)	(23,719,000)	[1]					(23,719,000)
Actuarial gains on defined benefit obligations	566,000					566,000
Foreign currency translation loss	(178,000)				28,000	(206,000)
Total comprehensive (loss)	(23,331,000)				28,000	360,000	(23,719,000)
Allocation of prior period income (loss)	0				(63,984,000)		63,984,000
Exercise and subscription of equity instruments (in shares)								41,050	(85)
Exercise and subscription of equity instruments	61,000		2,000	59,000
Shared-based payment	853,000			853,000
Balance at end of period (in shares) at Jun. 30, 2021								79,027,540	14,377
Balance at end of period at Jun. 30, 2021	133,561,000		3,952,000	373,043,000	(220,431,000)	715,000	(23,719,000)
Balance at beginning of period (in shares) at Dec. 31, 2021								79,542,627	14,095
Balance at beginning of period at Dec. 31, 2021	107,440,000		3,978,000	375,220,000	(219,404,000)	456,000	(52,809,000)
Net income (loss)	6,303,000						6,303,000
Actuarial gains on defined benefit obligations	471,000					471,000
Foreign currency translation loss	(670,000)				(28,000)	(642,000)
Total comprehensive (loss)	6,104,000				(28,000)	(171,000)	6,303,000
Allocation of prior period income (loss)	0				(52,809,000)		52,809,000
Exercise and subscription of equity instruments (in shares)								211,030
Exercise and subscription of equity instruments	191,000		10,552	180,891
Shared-based payment	2,596,000			2,596,000
Balance at end of period (in shares) at Jun. 30, 2022								79,753,657	14,095
Balance at end of period at Jun. 30, 2022	€ 116,333,000		€ 3,988,388	€ 377,998,000	€ (272,241,000)	€ 284,000	€ 6,303,000
[1]Comparative relating to the six months ended June 30, 2021 have been restated to reflect the impact of the classification of Lumoxiti's activities as discontinued operations in 2021. See note 17 of the interim condensed consolidated financial statements as of June 30, 2022.

The Company and key events

The Company and key events	6 Months Ended
	Jun. 30, 2022
Company Information [Abstract]
The Company and key events	The Company and key eventsThe company Innate Pharma SA (the “Company” and, with its subsidiary, referred to as the “Group”), is a global, clinical-stage oncology-focused biotech company dedicated to improving treatment and clinical outcomes for patients through therapeutic antibodies that harness the immune system to fight cancer. Company’s broad pipeline of antibodies includes several potentially first-in-class clinical and preclinical candidates in cancers with high unmet medical need. The company is a pioneer in the understanding of Natural Killer cell biology and has expanded its expertise in the tumor microenvironment and tumor-antigens, as well as antibody engineering. This innovative approach has resulted in a diversified proprietary portfolio and major alliances with leaders in the biopharmaceutical industry including Bristol-Myers Squibb, Novo Nordisk A/S, Sanofi, and a multi-products collaboration with AstraZeneca. Since its creation, the Company has suffered losses due to its research and development ("R&D") activities. The first half of 2022 generated a net income of 6,303 thousand euros. As of June 30, 2022, shareholders' equity amounted to 116,333 thousand euros. Subject to receiving new milestone payments related to its collaboration agreements, the Company expects to incur additional losses until, if necessary, it can generate significant revenues from its product candidates in development. The Company’s future operations are highly dependent on a combination of factors, including: (i) the success of its R&D; (ii) regulatory approval and market acceptance of the Company’s future product candidates; (iii) the timely and successful completion of additional financing; and (iv) the development of competitive therapies by other biotechnology and pharmaceutical companies. As a result, the Company is and should continue, in the short to mid-term, to be financed through partnership agreements for the development and commercialization of its drug candidates and through the issuance of new equity instruments. The activity of the Company is not subject to seasonal effects. As of June 30, 2022, the Company had one wholly owned subsidiary: Innate Pharma, Inc., incorporated under the laws of Delaware in 2009. Innate Pharma is based in Marseille, France and listed on Euronext Paris and Nasdaq in the U.S., and had 213 employees as of June 30, 2022. • On April 29, 2022, the Company announced the inclusion of the first patient in the “PACIFIC-9” Phase 3 trial evaluating durvalumab in combination with monalizumab or oleclumab in patients with lung cancer. Under the monalizumab collaboration and license agreement entered into with AstraZeneca in 2015, AstraZeneca paid on June 17, 2022 a payment of $50.0 million (€47.7 million). • On June 1, 2022, the Company signed an amendment to the collaboration and license option agreement IPH5201 concluded with AstraZeneca in October 2018. Subsequently, the Company announced on June 3, 2022 the progress of IPH5201 towards a study of Phase 2 in lung cancers for which the Company will be the sponsor. In accordance with the amendment signed on June 1, 2022, the Company is eligible for a milestone payment of $5.0 million by AstraZeneca. This milestone payment was received on August 2, 2022 by the Company for an amount of €4.9 million. • During the period, the Company received from AstraZeneca a notice that it will not exercise its option to license the four preclinical programs covered in the "Future Programs Option Agreement". This option agreement was part of the 2018 multi-term agreement between AstraZeneca and the Company under which the Company received an upfront payment of $20.0 million ( €17.4 million). Innate has now regained full rights to further develop the four preclinical molecules. Consequently, the entire initial payment of $20.0 million, or €17.4 million was recognized as revenue as of June 30, 2022

Basis of presentation and state

Basis of presentation and statement of compliance	6 Months Ended
	Jun. 30, 2022
Significant Accounting Policies [Abstract]
Basis of presentation and statement of compliance	Basis of presentation and statement of complianceBasis of preparation The interim condensed consolidated financial statements as of June 30, 2022 and for the six months ended June 30, 2022 and 2021 and the related notes (together, the “interim condensed consolidated financial statements”) have been prepared under the responsibility of the management of the Company in accordance with the underlying assumptions of going concern as the Company’s loss-making situation is explained by the innovative nature of the products developed, therefore involving a multi-year research and development phase. The interim condensed consolidated financial statements were closed by the Executive Board, approved and authorized by the Supervisory Board upon recommendation of the Audit Committee on September 14, 2022. They have been prepared in accordance with IAS 34, ‘Interim Financial Reporting’ as issued by the International Accounting Standard Board (“IASB”). Due to the listing of ordinary shares of the Company on Euronext Paris and in accordance with the European Union’s regulation No. 1606/2002 of July 19, 2002, the interim condensed consolidated financial statements are also prepared in accordance with IFRS, as adopted by the European Union (EU).For the presented periods, the differences between IFRS as issued by IASB and IFRS adopted by EU had no impact on the interim condensed consolidated financial statements. The general accounting conventions were applied in accordance with the underlying assumptions, namely (i) going concern, (ii) permanence of accounting methods from one year to the next and (iii) independence of financial years, and in conformity with the general rules for the preparation and presentation of consolidated financial statements in accordance with International Financial Reporting Standards (“IFRS”). The interim condensed consolidated financial statements do not include all disclosures required for annual financial statements and should therefore be read in conjunction with the consolidated financial statements as of and for the year ended December 31, 2021. The results of the operations for the six months ended June 30, 2022 are not necessarily indicative of the results to be expected for the year ending December 31, 2022 or for any other interim period or for any year in the future. Except for number of shares and per share amounts, all amounts are expressed in thousands of euros, unless stated otherwise. Some amounts may be rounded for the calculation of financial information contained in the interim condensed consolidated financial statements. Accordingly, the totals in some tables may not be the exact sum of the preceding figures. The preparation of financial statements in accordance with IFRS requires the Company to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expenses during the reporting period. These estimates can be revised where the circumstances on which they are based change. The actual results may therefore differ from the estimates initially formulated. The estimates and judgments which are mainly used by the Company are detailed in note 18.1.1 in paragraph 2.w) of the appendix to the consolidated financial statements as of December 31, 2021 of the Universal Registration Document published on April 24, 2022. Estimates and judgments which impact the condensed consolidated financial statements at June 30, 2022 are: • accounting for collaboration and licensing agreements (note 6 and 13); • estimate of the recoverable amount of the acquired and under progress licenses (note 6); • estimate of the useful life of the acquired licenses (note 6). Recently issued accounting standards and interpretations Application of the following amended standards is mandatory for the first time for the financial period beginning on January 1, 2022 and, as such, they have been adopted by the Company: • Amendments to IAS 16: Property, Plant and Equipment • Amendments to IAS 37 : Provisions, Contingent Liabilities and Contingent Assets Those amended standards have no impact on the interim condensed consolidated financial statements. Foreign currency transactions are translated into the presentation currency using the following exchange rates: June 30, 2021 December 31, 2021 June 30, 2022 €1 equals to Average rate Closing rate Average rate Closing rate Average rate Closing rate USD 1.2053 1.1824 1.1827 1.1326 1.0933 1.0387

Management of financial risks

Management of financial risks	6 Months Ended
	Jun. 30, 2022
Disclosure of nature and extent of risks arising from financial instruments [abstract]
Management of financial risks	Management of financial risksThe Company did not identify other risks than the ones presented in the consolidated financial statements as of and for the year ended December 31, 2021.

Cash, cash equivalents, short-t

Cash, cash equivalents, short-term investments and non-current financial assets	6 Months Ended
	Jun. 30, 2022
Subclassifications of assets, liabilities and equities [abstract]
Cash, cash equivalents, short-term investments and non-current financial assets	Cash, cash equivalents, short-term investments and non-current financial assets (in thousands of euro) June 30, 2022 December 31, 2021 Cash and cash equivalents 102,949 103,756 Short-term investments 20,401 16,080 Cash, cash equivalents and short-term investments 123,350 119,836 Non-current financial assets 34,806 39,878 Cash, cash equivalents and financial assets 158,156 159,714 Cash and cash equivalents are mainly composed of current bank accounts, interest-bearing accounts and fixed-term accounts. As of June 30, 2022, the Company also holds seven units in “SICAVs” and shares in mutual funds. The risk profiles of these funds are rated from 1 to 7 by the financial institution that manages and markets these funds (1 being the lowest risk profile).When the maturity of shares in mutual funds is longer than one year, they are classified as non-current financial instruments. Non-current financial assets generally include a guarantee of capital at the maturity date (which is always longer than one year). These instruments are defined by the Company as financial assets at fair value through profit or loss and classified as non-current due to their maturity. As of June 30, 2022 and December 31, 2021, the amount of cash, cash equivalents and financials assets denominated in US dollars amounted to €42,505 thousand and €47,164 thousand, respectively. Changes in short-term investments and non-current financial assets for the six months ended June 30, 2021 and 2022 are the following: (in thousands of euro) December 31, 2021 Additions (1) Deductions (2) Variance of fair value through the consolidated statement of income (loss) Variation of accrued interests Foreign currency effect June 30, 2022 Short-term investments 16,080 2,935 — 53 — 1,333 20,401 Non-current financial assets 39,878 — (2,935) (2,308) 172 — 34,806 Total 55,958 2,935 (2,935) (2,255) 172 1,333 55,207 (in thousands of euro) December 31, 2020 Additions Deductions Variance of fair value through the consolidated statement of income (loss) Variation of accrued interests Foreign currency effect June 30, 2021 Short-term investments 14,845 — — 53 — 443 15,341 Non-current financial assets 38,934 — — 978 170 — 40,083 Total 53,779 — — 1,031 170 443 55,424 (1) The additions correspond to both acquisitions and reclassifications of financial assets according to their maturity at the closing date . (2) The deductions correspond to both disposals and reclassifications of financial assets according to their maturity at the closing date. In the six months ended June 30, 2022 , variance of fair value through the consolidated statement of income (loss) is made of €2,308 thousand of unrealized loss on non-current financial assets and €53 thousand of unrealized gains on short-term investments. In the six months ended June 30, 2021, variance of fair value through the consolidated statement of income (loss) was made of €978 thousand of unrealized gains on non-current financial assets and €53 thousand of unrealized gains on short-term investments (see note 16).

Trade receivables and others

Trade receivables and others	6 Months Ended
	Jun. 30, 2022
Subclassifications of assets, liabilities and equities [abstract]
Trade receivables and others	Trade receivables and others (in thousands of euro) June 30, 2022 December 31, 2021 Other receivables 78 814 Research tax credit(1) 31,309 10,310 Other tax credits 333 333 Prepaid expenses 3,688 2,582 VAT refund 1,545 1,170 Trade account receivables (2) 8,565 846 Prepayments made to suppliers 2,929 2,364 Receivables and others 48,447 18,420 Research tax credit(1) 13,084 29,821 Receivables and others - non-current 13,084 29,821 Trade receivables and others 61,531 48,241 (1) The Research tax credit is recognized as other operating income in the year to which the eligible research expenditure relates. The amount of €13,084 thousand recognized in non-current receivables corresponds to the CIR for the 2020 tax year following the fact that the Company no longer meets the eligibility criteria for the SME status as of December 31, 2019. As of December 31, 2020 and 2021 respectively, the Company has ensured that the eligibility criteria for the SME status are met again. The Company is therefore eligible for the early repayment by the French treasury during the fiscal year 2022 of the 2021 Research Tax Credit for an amount of €10,302 thousand. This amount has not yet been received by the Company as of June 30, 2022 and is classified as current receivable in the same way as the CIR for the 2019 tax year, for an amount of €16,737 thousand, and the first half of 2022 for an amount of €4,270 thousand. (2) As of June 30,2022, this amount includes a receivable of €4,676 thousand linked to the IPH5201 collaboration and license option agreement. This receivable follows the signature on June 1, 2022 of an amendment to the initial contract signed in October 2018. This amendment formalizes the terms of the collaboration following AstraZeneca's decision to advance IPH5201 to a Phase 2 study. This amount was paid to the Company in August 2022. In addition, there is a receivable of €3,000 thousand linked to the collaboration and licensing agreement signed with Sanofi in January 2016. This receivable resulted from the decision taken by Sanofi to advance IPH6401/SAR'514 towards regulatory preclinical studies for the study of a new investigational drug. This payment was received by the Company in January 2021. The net book value of the receivables is considered to be a reasonable approximation of their estimated fair value. Trade receivables and others have payment terms of less than one year. No valuation allowance was recognized on trade receivables and others as the credit risk of each debtor was considered as not significant.

Intangible assets

Intangible assets	6 Months Ended
	Jun. 30, 2022
Intangible assets other than goodwill [abstract]
Intangible assets	Intangible assets (in thousands of euro) Purchased licenses Other intangible assets In progress Total January 1, 2021 5,103 185 41,000 46,289 Acquisitions — 13 — 13 Additional considerations — — — — Disposals — — — — Amortizations (1,039) (1) (70) — (1,109) Transfers — — — — June 30, 2021 4,064 128 41,000 45,193 January 1, 2022 3,161 29 41,000 44,192 Acquisitions — — — — Additional considerations — — — — Disposals — — — — Amortizations (940) (1) — — (940) Transfers — — — — June 30, 2022 2,221 29 41,000 43,260 (1) As of June 30,2021, this amount related in its entirety to the amortization of rights related to the monalizumab. As of June 30, 2022, this amount includes the amortization of rights related to the monalizumab for an amount of €903 thousand. Monalizumab rights under the 2014 monalizumab (NKG2A) Novo Nordisk agreement Since their acquisition, monalizumab rights are amortized on a straight-line basis over the anticipated residual duration of the Phase II trials. The Company has reassessed the anticipated residual duration of the Phase 2 trials as of June 30, 2022 and estimated that it would be fully amortized by 2023, which is the same estimation as of December 31, 2021, as a result of the completion of some trials and by modifying the estimated end dates relating to certain cohorts. The net book values of the monalizumab rights were €2,252 thousand and €3,155 thousand as of June 30, 2022 and December 31, 2021, respectively. IPH5201 (Anti-CD39) rights acquired from Orega Biotech This asset was amortized on a straight-line basis since November 1, 2018 (corresponding to the effective beginning date of the collaboration) until the date the Company expected to fulfill its commitment (end of fiscal year 2020). These collaboration commitments have all been fulfilled. Thus, the rights relating to IPH5201 have been fully amortized since December 31, 2020. As a reminder, Orega Biotech claimed joint ownership of certain patents relating to IPH5201. The Company and Orega Biotech have resolved these claims in an arbitration proceeding, which decision was rendered in December 2021. As a result of this decision, the Company is required to pay a low-teen percentage of sub-licensing revenues received by the Company pursuant to its agreement with AstraZeneca regarding IPH5201. Following this arbitration decision, the Company paid in January 2022 an additional amount of €0.4 million to Orega. This additional payment was fully amortized as of December 31, 2021. Avdoralimab (IPH5401) (anti-C5aR) rights acquired from Novo Nordisk A/S At the agreement inception, an upfront payment of €40 million for acquired rights were recorded as intangible asset. As part of this agreement, an additional amount of €1.0 million was paid in October 2020 to Novo Nordisk A / S following the launch of the first avdoralimab Phase II trial. As avdoralimab is still in clinical trial, the acquired rights are classified as intangible asset in progress. They were subject to annual impairment test. No impairment were recorded since inception. These acquired rights will be amortized when the Company obtains economic benefits. According to the agreement, the Company will pay additional payments according to the reach of specific steps. As of June 30, 2022, according to the uncertainty of these potential future payments, no liability was recognized. Development costs incurred by the Company are recognized as research and development expenses. As of June 30, 2022, the Company has not identified any indication of impairment of the avdoralimab rights in the first half of 2022. As a reminder, the Company had performed an impairment test as of December 31, 2021, in accordance with IAS 36 "Impairment of assets". The Company applied IAS 36 "Impairment of assets" and assessed whether there was any indication of impairment that could lead to the impairment of a recognized intangible asset. The Company estimated the recoverable amount of the unamortized intangible asset avdoralimab using a discounted cash flow model which confirmed that no impairment is required. The following main assumptions were used to determine the recoverable amount, based on the cash flows determined using the marketing plan and budget approved by management : • Cash flows are set on the basis of the development and commercialization plans and budgets approved by Management; • A discount rate of 11%; • A risk of development is taken into consideration by applying probabilities of success of reaching future phases of development to cash flows related to each development phases; Those average probabilities of success of R&D projects are based on an article published in Nature Review Drug Discovery; • For the commercialization phase, selling price and sales volume are estimated on the basis of the potential market and the observed performances of comparable drugs currently on the market. Decrease in sales volume applied to the forecasted revenue once the related rights fall off-patent. In case of failure of the clinical trials in progress, the Company may have to depreciate the intangible asset corresponding to the avdoralimab rights. The Company did not identify any reasonable potential variance in the key assumptions that may generate an impairment as of June 30, 2022. Sensitivity testing regarding these following assumptions and other assumptions such as: discount rate (+1%), decrease in sales volume (- 25%) and growth rate at termination (-1%) were performed. These tests did not reveal any impairment. Avdoralimab does not generate economic benefits yet for the Company. In accordance with IAS 38, it will be amortized when it generates economic benefits, which can result from: • The drug candidate commercialization ; or, • An out-licensed agreement. If the Company commercialize the drug product on its own, it will have to determine the amortization period of the related capitalized rights. It will have to estimate their useful life, considering the date when they fall off patent. Those capitalized rights will be amortized on a straight line basis during the estimated useful life.

Property and equipment

Property and equipment	6 Months Ended
	Jun. 30, 2022
Property, plant and equipment [abstract]
Property and equipment	Property and equipment (in thousands of euro) Lands and buildings Laboratory equipment and other In progress Total Of which finannce leases January 1, 2021 5,751 5,576 367 11,694 6,423 Acquisitions — 260 — 260 — Disposals — (2) — (2) — Depreciation (393) (668) — (1,061) (535) Transfers — 4 (4) — — June 30, 2021 5,358 5,170 363 10,891 5,888 (in thousands of euro) Lands and buildings Laboratory equipment and other In progress Total Of which right of use assets(3) January 1, 2022 4,981 5,187 6 10,174 5,342 Acquisitions 14 458 — 472 — Disposals — — — — — Depreciation (379) (711) — (1,090) (534) Transfers — — — — — June 30, 2022 4,616 4,934 6 9,556 4,808

Trade payables and others

Trade payables and others	6 Months Ended
	Jun. 30, 2022
Subclassifications of assets, liabilities and equities [abstract]
Trade payables and others	Trade payables and others (in thousands of euro) June 30, 2022 December 31, 2021 Suppliers (excluding payables related to capital expenditures) 12,924 14,729 Tax and employee-related payables 5,478 7,463 Other payables 13 6,380 Trade payables and others (excluding payables related to capital expenditures) 18,415 28,573 Payables related to capital expenditures 252 — Payables and others 18,667 28,573 The book value of trade payables and others is considered to be a reasonable approximation of their fair value.

Financial liabilities

Financial liabilities	6 Months Ended
	Jun. 30, 2022
Subclassifications of assets, liabilities and equities [abstract]
Financial liabilities	Financial liabilities (in thousands of euro) December 31, 2021 Proceeds from borrowing Proceeds from lease liabilities and other non cash effects Repayments of borrowings/leases liabilities Exchange rate variation (non cash) June 30, 2022 State guaranteed loan Société Générale (1) 20,000 — 50 — — 20,050 State guaranteed loan BNP Paribas (1) 8,700 — 22 — — 8,722 Lease liabilities – Building "Le Virage" 1,875 — — (260) — 1,614 Lease liabilities – Premises Innate Inc. 391 — 45 (44) 5 396 Lease liabilities – Laboratory equipment 464 — — (87) — 376 Lease liabilities – Vehicles 53 — 38 (19) — 71 Lease liabilities - Printers 35 — — (4) — 31 Borrowing – Equipment 209 — — (27) — 181 Borrowing – Building 12,525 — — (591) — 11,933 Total 44,252 — 155 (1,032) 5 43,374 (in thousands of euro) December 31, 2020 Proceeds from borrowing Proceeds from lease liabilities (non cash) Repayments of borrowings/leases liabilities Exchange rate variation (non cash) June 30, 2021 BPI PTZI IPH41 150 — — (150) — — Lease liabilities – Real estate property 1,454 — (1,454) — — — Lease liabilities – Building "Le Virage" 2,387 — — (255) — 2,131 Lease liabilities – Premises Innate Inc. 447 — — (18) (5) 423 Lease liabilities – Laboratory equipment 639 — — (87) — 551 Lease liabilities – Vehicles 21 — — (6) — 14 Lease liabilities - Printers 41 — — (2) — 39 Borrowing – Equipment 262 — — (25) — 236 Borrowing – Building 13,687 — — (579) — 13,107 Total 19,087 — (1,454) (1,121) (5) 16,502 (1) On January 5, 2022, the Company announced that it had obtained €28.7 million in non-dilutive financing in the form of two State Guaranteed Loans from Société Générale (€20.0 million) and BNP Paribas (€8.7 million). The Company received the funds related to these two loans on December 27 and 30, 2021 respectively. Both loans have an initial maturity of one year with an option to extend to five years usable from August, 2022. They are 90% guaranteed by the French government as part of the package of measures put in place by the French government to support companies during the COVID-19 pandemic. As of June 30, 2022, the Company was not able to use the options to extend the principal repayment of these loans. Thus, at the same date, the effective interest rate applied to these contracts is 0.5% which is the contractual rate for repayment within one year. In August 2022, the Company communicated to Société Générale and BNP Paribas its desire to use the capital repayment extension options of the two State-Guaranteed Loans (“PGE”) contracted in December 2021 (see note 21). Finance lease obligations relate primarily to real estate property in relation to the acquisition in 2008 of the Company’s headquarters and main laboratories. They are presented in the above table net of the cash collateral paid to Sogebail, the lessor. On July 3, 2017, the Company borrowed from the Bank “Société Générale” in order to finance the construction of its future headquarters. This loan amounting to a maximum of €15,200 thousand will be raised during the period of the construction in order to pay the supplier payments as they become due. As of December 31, 2018 and 2019, the loan was raised at an amount of €1,300 thousand. The loan release period was limited to August 30, 2019. On August 30, 2019, the Company drew down the remaining portion of the €15,200 thousand loan granted, for an amount of €13,900 thousand. The reimbursement of the capital has begun in August 30, 2019 and will proceed until August 30, 2031 (12 years). Given the development of its portfolio and in particular the refocusing of its activities on research and development, the Company has for the time being suspended the project to build its new head office on the land acquired in Luminy. In the meantime, the loan will be used to finance several structuring projects (improvement of the information system, development of a commercial platform, development of additional premises rented, etc.). As of June 30, 2022, the remaining capital of the loan amounted to €11,933 thousand. The Company authorized collateral over financial “Société Générale” instruments amounting to €15,200 thousand. The security interest on the pledge financial instruments will be released in accordance with the following schedule: €4,200 thousand in July 2024, €5,000 thousand in July 2027 and €6,000 thousand in July 2031. This loan bears a fixed interest rate of 2.01%. It is subject to a covenant based on the assumption that the total cash, cash equivalents and current and non-current financial assets are at least equal to principal as of financial year end. The table below shows the schedule for the contractual repayment of financial liabilities (being principal and interest payments) as of June 30, 2022: (in thousands of euro) Within 1 year From 2nd to 5th year included Over 5 years Total State guaranteed loan Société Générale 20,050 — — 20,050 State guaranteed loan BNP Paribas 8,722 — — 8,722 Lease liabilities – Building "Le Virage" 527 1,088 — 1,614 Lease liabilities – Premises Innate Inc. 91 299 — 396 Lease liabilities – Laboratory equipment 178 199 — 376 Lease liabilities – Vehicles 29 44 — 71 Lease liabilities - Printers 9 22 — 31 Borrowing – Equipment 55 126 — 181 Borrowing – Building 1,198 5,039 5,697 11,933 Total financial liabilities 30,859 6,817 5,697 43,374

Employee benefit

Employee benefit	6 Months Ended
	Jun. 30, 2022
Disclosure of information about defined benefit plans [abstract]
Employee benefit	Employee benefit Defined benefit obligation (in thousands of euro) June 30, 2022 December 31, 2021 Allowance for retirement defined benefit 2,306 2,544 Allowance for seniority awards 390 432 Defined benefit obligations 2,696 2,975 Amounts recognized in the statement of financial position are determined as follows (in thousand euros): As of January 1, 2021 4,177 IAS19 Restatement related to change in calculation method - IFRIC (1) (1,054) As of January 1, 2021 Restated 3,123 Service cost 484 Interest costs (47) Actuarial (gain) / loss (584) As of December 31, 2021 2,976 Service cost 205 Interest costs (14) Actuarial (gain) / loss (471) As of June 30, 2022 2,696 (1) As a reminder, in its April 2021 Update, the IFRS IC published a final agenda decision clarifying how to calculate the obligation relating to certain defined benefit plans. The effects of this change of method are therefore taken into account retrospectively as of January 1, 2021 in respect of 2020's and prior years defined benefit obligation. The adjustment at that date corresponds to a reduction in the 2020 commitments in the amount of €1,054 thousand. This reversal has been offset against previous reserves and retained earnings. Discount rates used by the Company to evaluate retirement benefits were based on iBoxx Corporate AA. They amounted to 3.20% and 0.95% as of June 30, 2022 and December 31, 2021, respectively.

Capital

Capital	6 Months Ended
	Jun. 30, 2022
Share Capital and Share Base Payments [Abstract]
Capital	CapitalShare capital The Company manages its capital to ensure that the Company will be able to continue as a going concern while maximizing the return to shareholders through the optimization of the debt and equity balance. As of June 30, 2022, the Company’s share capital amounted to €3,988,388 divided into (i) 79,753,657 ordinary shares, each with a nominal value of €0.05; (ii) 6,514 “2016” preferred shares, each with a nominal value of €0.05, and (iii) 7,581 “2017” preferred shares, each with a nominal value of €0.05, respectively, fully paid up. Share capital does not include BSAs, BSAAR, AGAs and AGAPs that have been granted to certain investors or natural persons, both employees and non-employees of the Company, but not yet exercised. On October 21, 2019 and December 30, 2019, the retention period for the “2016 free preferred shares” has ended. The number of ordinary shares to which the conversion of one preferred share entitle has been determined according to the fulfilment of the performance criteria. Holders of “2016” preferred shares” are entitled to vote at our shareholders’ meetings, to dividends and to preferential subscription rights, on the basis of the number of ordinary shares to which they are entitled if they convert their preferred shares. In April 3, 2021, the retention period for the "2017 free preferred shares" has ended. The number of ordinary shares to which the conversion of one preferred share entitle has been determined according to the fulfillment of the performance criteria. According to these same performance criteria, the Executive Board of April 7, 2021 noted that the "2017 preferred shares" did not give right to any ordinary shares. The “2017 preferred shares” will not be redeemed by the Company and will remain incorporated into the capital, unless subsequently decided by the Executive Board. As the conversion is void, the "2017 preferred shares" no longer give the right to vote at our general meetings, nor to receive dividends. In the six months ended June 30, 2022, a capital increase of €10,552 occurred as a result of the Executive Board decisions on February 14, 2022 and April 22, 2022, subsequent to (i) the conversion of 750 “2012” BSAAR and (ii) the creation of 185,280 ordinary shares following the set-up of a company saving plan for the benefit of the Company’s employees, including 138,960 ordinary shares issued free of charge (top-up) and the definitive acquisition of 25,000 free shares allocated on April 29, 2019 under the “AGA New Members 2017” plan. These events led to a net capital increase of €10,552 and an increase in share premium of €180,891, broken down as follows: (i) a creation of 750 ordinary shares, with a nominal value of €0.05, for an issue price of €2.04, (ii) a creation of 138,960 ordinary shares, with a nominal value of €0.05 and a creation of 46,320 ordinary shares, with a nominal value of €0.05, for an issue price of €4.10 per share, and (iii) a creation of 25,000 ordinary shares, with a nominal value of €0.05. The Company held 18,575 of its own shares as of June 30, 2022 and December 31, 2021, respectively. Date Types Number of warrants issued as of 6/30/2022 Number of warrants void as of 6/30/2022 Number of warrants exercised as of 6/30/2022 Number of warrants outstanding as of 6/30/2022 Maximum number of shares to be issued as of 6/30/2022 Exercise price per share (in €) Sept. 9, 2011 BSAAR 2011 650,000 25,000 625,000 — — 2.04 May 27, 2013 BSAAR 2012 146,050 — 86,700 59,350 59,350 2.04 July 1, 2015 BSAAR 2015 1,050,382 2,720 1,940 1,045,722 1,045,722 7.20 October 21, 2016 AGAP Management 2016-1 2,000 550 250 86,700 59,350 59,350.00 October 21, 2016 AGAP Employees 2016-1 2,486 251 167 2,068 268,840 - October 21, 2016 AGA Management 2016-1 50,000 — 50,000 — — - December 30, 2016 AGAP Management 2016-2 3,000 — — 3,000 333,000 - December 30, 2016 AGA Management 2016-2 250,000 — 250,000 — — - April 3,2018 AGAP Employees 2017-1 5,725 5,725 — — — - April 3,2018 AGAP Management 2017-1 2,400 2,400 — — — — April 3,2018 AGA Employees 2017 114,500 4,000 110,500 — — — July 3, 2018 AGA Bonus 2018-1 67,028 469 66,559 — — - November 20, 2018 AGAP Perf Employees 2018-1 327,500 224,375 103,125 — — - November 20, 2018 AGAP Perf Management 2018-1 260,000 150,000 110,000 — — - January 14, 2019 AGA Employees 2018 90,650 5,000 85,650 — — - April 29, 2019 AGA New Members 2017-1 25,000 — 25,000 — — - July 3, 2019 AGA Bonus 2019-1 57,376 — 57,376 — — - July 13, 2020 AGA Bonus 2020-1 79,861 17,885 48,362 13,614 13,614 - August 5, 2020 AGAP Employees 2020-1 766,650 269,282 — 497,368 497,368 - August 5, 2020 AGAP Management 2020-1 710,000 60,000 — 650,000 650,000 - July 22, 2021 AGA Bonus 2021-1 125,748 — — 125,748 125,748 - October 1, 2021 AGAP Employees 2021-1 1,066,600 67,800 — 998,800 998,800 - October 1, 2021 AGAP Management 2021-1 610,000 90,000 — 520,000 520,000 - July 21, 2020 Stock Options 2020-1 102,000 102,000 — — — - November 4, 2019 AGAP 2019 Employees 2019 546,700 202,400 — 344,300 344,300 - November 4, 2019 AGAP 2019 Management 2019 355,000 60,000 — 295,000 295,000 - July 29, 2011 BSA 2011-2 225,000 25,000 200,000 — — 1.77 July 17, 2013 BSA 2013 237,500 — 191,140 46,360 46,360 2.36 July 16, 2014 BSA 2014 150,000 — 75,000 75,000 75,000 8.65 April 27, 2015 BSA 2015-1 70,000 — — 70,000 70,000 9.59 July 1, 2015 BSA 2015-2 14,200 — — 14,200 14,200 14.05 September 20, 2017 BSA 2017 37,000 — — 37,000 37,000 11.00 Total as of June 30, 2022 8,200,356 1,314,857 2,061,019 4,824,480 5,576,052

Financial instruments recognize

Financial instruments recognized in the statement of financial position and related effect on the income statement	6 Months Ended
	Jun. 30, 2022
Disclosure of detailed information about financial instruments [abstract]
Financial instruments recognized in the statement of financial position and related effect on the income statement	Financial instruments recognized in the statement of financial position and related effect on the income statement The following tables show the carrying amounts and fair values of financial assets and financial liabilities. The tables do not include fair value information for financial assets and financial liabilities not measured at fair value if the carrying amount is a reasonable approximation of fair value. As of June 30, 2022 Book value on the statement of financial position Fair value through profit and loss (1) Amortized cost (2) Fair value Financial assets Non-current financial assets 34,806 34,806 — 34,806 Trade receivables and others 61,531 — 61,531 61,531 Short-term investments 20,401 20,401 — 20,401 Cash and cash equivalents 102,949 102,949 — 102,949 Total financial assets 219,687 158,156 61,531 219,687 Financial liabilities Financial liabilities—non-current portion 12,523 — 12,523 12,523 Financial liabilities—current portion 30,851 — 30,851 30,851 Trade payables and others 18,667 — 18,667 18,667 Total financial liabilities 62,041 — 62,041 62,041 As of December 31, 2021 Book value on the statement of financial position Fair value through profit and loss (1) Amortized Cost (2) Fair value Financial assets Non-current financial assets 39,878 39,878 — 39,878 Trade receivables and others 48,241 — 48,241 48,241 Short-term investments 16,080 16,080 — 16,080 Cash and cash equivalents 103,756 103,756 — 103,756 Total financial assets 207,955 159,714 48,241 207,955 Financial liabilities Financial liabilities—non-current portion 13,503 — 13,503 13,503 Financial liabilities—current portion 30,748 — 30,748 30,748 Trade payables and others 28,573 — 28,573 28,573 Total financial liabilities 72,824 — 72,824 72,824 ( 1) The fair value of financial assets classified as fair value through profit and loss corresponds to the market value of the assets, which are primarily determined using level 2 measurements. (2) The book amount of financial assets and liabilities measured at amortized cost was deemed to be a reasonable estimation of fair value. In accordance with the amendments to IFRS 7, financial instruments are presented in three categories based on a hierarchy of methods used to determine fair value: Level 1: fair value determined based on quoted prices in active markets for assets or liabilities; Level 2: fair value determined on the observable database for the asset or liability concerned either directly or indirectly;

Revenue, government financing f

Revenue, government financing for research expenditures and sales	6 Months Ended
	Jun. 30, 2022
Disclosure of disaggregation of revenue from contracts with customers [abstract]
Revenue, government financing for research expenditures and sales	Revenue, government financing for research expenditures and salesRevenue from collaboration and licensing agreements Revenues from collaboration and licensing agreements result from agreements signed with AstraZeneca and Sanofi : (in thousands of euro) June 30, 2022 June 30, 2021 Proceeds from collaboration and licensing agreements 41,919 7,095 of which monalizumab agreement (AstraZeneca) 16,440 6,095 of which IPH5201 agreement (AstraZeneca) 4,826 — of which preclinical molecules agreement (AstraZeneca) 17,400 — of which Sanofi agreement 3,000 1,000 of which other agreements 252 — Invoicing of R&D costs (IPH5201 and advoralimab agreements) (21) 1,209 Exchange gains or losses on collaboration agreement (627) — Revenue from collaboration and licensing agreements 41,271 8,304 a) Revenue recognition related to monalizumab AZ agreements and amendments Change in deferred revenue relating to monalizumab agreement: (in thousands of euro) Total As of December 31, 2020 26,572 Revenue for the six months ended June 30, 2021 (6,095) Transfer from / (to) collaboration liabilities 188 As of June 30, 2021 20,665 As of December 31, 2021 20,159 Increase in deffered revenu resulting from the $50m milestone relating to the dosage of the first patent in the Phase 3 trial PACIFIC-9 47,687 Revenue for the six months ended June 30, 2022 (16,440) Transfer from / (to) collaboration liabilities (34,094) As of June 30, 2022 17,312 (1) The increase in deferred revenue relating to monalizumab agreement between December 31, 2021 and June 30, 2022 is explained by the additional payment of €47,687 thousand ($50,000 thousand) made by AstraZeneca in June 2022 and triggered by the launch of the “PACIFIC-9” Phase 3 trial on April 28, 2022. This increase has led to a simultaneous increase in collaboration commitment ("collaboration liability"- see below) of €34,335 thousand ($36,000 thousand) in accordance with the Company’s July 2019 option concerning the co-financing of Phase 3 trials in the field of collaboration. Change in collaboration liabilities relating to monalizumab agreement: (in thousands of euro) Total As of December 31, 2020 46,686 Revenue for the six months ended Additions 1,501 Deductions (2,253) As of June 30, 2021 45,934 As of December 31, 2021 40,415 Revenue for the six months ended Additions (1) 38,568 Deductions (5,862) As of June 30, 2022 73,121 (1) The increase in collaboration liabilities relating to monalizumab agreement between December 31, 2021 and June 30, 2022 mainly results from (i) a €34,335 thousand ($36,000 thousand) increase in collaboration commitments in connection with the launch of the “PACIFIC-9” Phase 3 trial on April 28, 2022, and (ii) a €3.7 million increase in the collaboration commitments in connection with exchange rate fluctuations over the period. b) Revenue recognition related to IPH5201 AstraZeneca collaboration and option agreement Revenue related to IPH5201 for the six months ended June 30, 2022 is €4,826 thousand and results from the entire recognition in revenue of the $5.0 million milestone payment received from AstraZeneca following the signature on June 1, 2022 of an amendment to the initial contract signed in October 2018. This amendment sets the terms of the collaboration following AstraZeneca’s decision to advance IPH5201 to a Phase 2 study. The Company will conduct the study. Both parties will share the external cost related to the study and incurred by the Company and AstraZeneca will provide products necessary to conduct the clinical trial. c) Revenue related to collaboration and option agreement related to four to-be-agreed upon molecules (preclinical molecules) Change in deferred revenue relating to the 2018 future programs option agreement (in thousands of euro) Total As of December 31, 2021 17,400 Augmentation — Deductions (17,400) As of June 30, 2022 — During the period, the Company received from AstraZeneca a notice that it will not exercise its option to license the four preclinical programs covered in the "Future Programs Option Agreement". Consequently, the entire initial payment of €17,400 thousand was recognized as revenue as of June 30, 2022. d) Revenue related to IPH6401 - Sanofi Revenue related to IPH6401 under the collaboration and license agreement signed with Sanofi is €3,000 thousand for the six months ended June 30, 2022, as compared to a revenue of €1,000 thousand as of June 30, 2021. During the period, the Company announced the decision taken by Sanofi to advance IPH6401/SAR’514 towards regulatory preclinical studies aimed at studying an investigational new drug. This selection triggered a €3.0 million milestone payment from Sanofi to the Company fully recognized in revenue as of June 30, 2022. This amount was received by the Company on September 9, 2022. e) Schedule of variance of deferred revenue (in thousands of euro) As of December 31, 2021 Recognition in P&L Proceeds Transfer from / (to) collaboration liabilities As of June 30, 2022 Monalizumab 20,159 (16,440) 47,687 (34,094) 17,310 IPH5201 — — — — — Preclinical molecules 17,400 (17,400) — — — Others 353 (235) — — 117 Total 37,912 (34,075) 47,687 (34,094) 17,427 (in thousands of euro) As of December 31, 2020 Recognition in P&L Proceeds Transfer from / (to) collaboration liabilities As of June 30, 2021 Monalizumab 26,572 (6,095) — 188 20,665 IPH5201 — — — — — Preclinical molecules 17,400 — — — 17,400 Total 43,973 (6,095) — 188 38,066 The Company receives grants from the European Commission, French government and state organizations in several different forms: • Research Tax Credits; and • Investment and operating grants. As of June 30, 2022 and 2021, an estimate of the research tax credit amount for the first half period is calculated on the basis of eligible expenses over the period. Since January 1, 2022, public subcontracting expenses are no longer taken into account for twice their amount in the CIR calculation. The total amount for government financing for research expenditures recorded as other income in the income statement can be analysed as follows: (in thousands of euro) June 30, 2022 June 30, 2021 Research tax credit 4,270 4,933 Grant 49 1,435 Government financing for research expenditures 4,319 6,368 As a reminder, as of June 30, 2021, the total amount of grants recognized in the income statement includes an amount of €1,360 thousand representing the first tranche related to the BPI financing contract signed in August 2020 as part of the program set up by the French government to help develop a therapeutic solution with a preventive or curative aim against COVID-19.

Operating expenses

Operating expenses	6 Months Ended
	Jun. 30, 2022
Analysis of income and expense [abstract]
Operating expenses	Operating expenses (in thousands of euro) June 30, 2022 June 30, 2021 (1) R&D G&A Total R&D G&A Total Subcontracting costs(2) (10,727) — (10,727) (10,179) (13) (10,193) Cost of supplies and consumable materials (1,663) (285) (1,948) (1,513) (666) (2,180) Personnel expenses other than share-based compensation (7,447) (4,448) (11,895) (6,827) (4,573) (11,400) Share-based compensation (1,275) (1,321) (2,596) (219) (633) (852) Personnel expenses (8,722) (5,769) (14,491) (7,046) (5,206) (12,252) Non-scientific advisory and consulting(3) (752) (2,242) (2,994) (175) (2,501) (2,676) Leasing and maintenance (97) (961) (1,058) (131) (1,017) (1,148) Travel expenses and meeting attendance (245) (109) (354) (22) (36) (58) Marketing, communication and public relations (84) (375) (459) (44) (115) (159) Scientific advisory and consulting(4) (360) — (360) 4 (83) (79) Other purchases and external expenses (9) (1,123) (1,132) — (1,255) (1,255) Depreciation and amortization (1,274) (768) (2,042) (1,473) (689) (2,161) Intellectual property expenses (492) (176) (668) (779) (20) (798) Other income and (expenses), net (531) (332) (863) 151 (1,043) (892) Total operating expenses (24,956) (12,140) (37,096) (21,208) (12,643) (33,851) (1) Items relating to the six months ended June 30, 2021 have been restated to reflect the impact of the classification of Lumoxiti's activities as discontinued operations in 2021. These items are presented in note 17. (2) The Company subcontracts a significant part of its pre-clinical (pharmaceutical development, tolerance studies and other model experiments, etc.) and clinical operations (coordination of trials, hospital costs, etc.) to third parties. (3) Non-scientific advisory and consulting are services performed to support the general and administration activities of the Company, such as legal, accounting and audit fees as well as business development support. (4) Scientific advisory and consulting expenses relate to consulting services performed by third parties to support the research and development activities of the Company.

Net financial income _ (loss)

Net financial income / (loss)	6 Months Ended
	Jun. 30, 2022
Analysis of income and expense [abstract]
Net financial income / (loss)	Net financial income / (loss) Net financial income (loss) can be analyzed as follows : (in thousands of euro) June 30, 2022 June 30, 2021 Interests on financial assets 198 171 Change in valuation allowance on financial instruments 53 1,040 Foreign exchange gains 3,797 2,185 Other financial income — 94 Financial income 4,048 3,490 Foreign exchange losses (3,663) (1,602) Unrealized losses on financial assets (2,309) — Interest on financial liabilities (194) (160) Other financial expenses — (18) Financial expenses (6,166) (1,781) Net financial income (loss) (2,118) 1,709 For the six months ended June 30, 2022 and 2021, the foreign exchange gains and losses mainly result from the variance of the exchange rate between the Euro and the US dollar on US dollars denominated cash and cash equivalent and financial assets accounts. Unrealized losses on financial assets relate to unquoted instruments, the fair value of which is determined using level 2 measurements.

Income tax _ (expense)

Income tax / (expense)	6 Months Ended
	Jun. 30, 2022
Income taxes paid (refund) [abstract]
Income tax / (expense)	Income tax / (expense) Due to the Company’s early stage of development, it is not probable that future taxable profit will be available against which the unused tax losses can be utilized. As a consequence, deferred tax assets are recognized up to deferred tax liabilities. The main temporary differences are related to the application of the IFRS 15 standard for fiscal years beginning on or after January 1, 2018, finance leases, provisions for pension commitments and tax loss carryforwards. The Company did not recognize a current tax expense as at June 30, 2022 regarding a projected tax rate of nil as of December 31, 2022. As of June 30, 2022, the accumulated tax losses carryforwards of Innate Pharma SA were €392,359 thousand with no expiration date (same amount as of December 31, 2021). As of June 30, 2022, the accumulated tax losses carryforwards of Innate Pharma Inc had tax losses that could be carried forward indefinitely and carried forward over a period of 20 years for the respective amounts of €14,967 thousand and €515 thousand for a total of €15,482 thousand or $16,081 thousand (same amount as of December 31, 2021).

Discontinued Operations

Discontinued Operations	6 Months Ended
	Jun. 30, 2022
Discontinued Operations [Abstract]
Discontinued Operations	Discontinued OperationsFurther to the decision to terminate the Lumoxiti Agreement and termination notice sent in December 2020, a Termination and Transition Agreement was discussed and executed, effective as of June 30, 2021 terminating the Lumoxiti Agreement as well as Lumoxiti related agreements (including the supply agreement, the quality agreement and other related agreements) and transferring of the U.S. marketing authorization and distribution rights of Lumoxiti back to AstraZeneca. Thus, the activities related to Lumoxiti are presented as a discontinued operation as of October 1, 2021 (and for all subsequent and prior period). a) Financial Performance (in thousands of euro) June 30, 2022 June 30, 2021 Revenue and other income Revenue from collaboration and licensing agreements — — Sales 42 1,015 Total revenue and other income 42 1,015 Operating expenses Research and development expenses (11) (586) Selling, general and administrative expenses (104) (6,678) Impairment of intangible assets — — Total operating expenses (115) (7,264) Net income (loss) from distribution agreements — — Operating income (loss) (73) (6,249) Financial income — — Financial expenses — — Net financial income (loss) — — Net income (loss) before tax (73) (6,249) Income tax expense — — Net income (loss) from discontinued operations (73) (6,249) b) Cash-Flows (in thousands of euro) June 30, 2022 June 30, 2021 Net cash generated from / (used in) operating activities (5,539) (4,398) Net cash generated from / (used in) investing activities — — Net cash generated from / (used in) financing activities — — Net cash flows from discontinued operations (5,539) (4,398)

Commitments, contingencies and

Commitments, contingencies and litigation	6 Months Ended
	Jun. 30, 2022
Commitments, Contingencies And Litigations [Abstract]
Commitments, contingencies and litigation	Commitments, contingencies and litigationCommitments The Company has identified the following changes in off-balance sheet commitments since December 31, 2021: • non-cancellable purchase commitments as of June 30, 2022 for a total of €2,666 thousand with various CMOs.These commitments are comprised of non-cancellable purchase orders placed during the first half of 2022 with contract manufacturing organizations (CMOs) for the supply of various services in relation with preclinical work for an amount of €2,485 thousand and clinical work for an amount of €181 thousand. The execution of these services has not yet started at the date of this report.

Related party transactions

Related party transactions	6 Months Ended
	Jun. 30, 2022
Related party transactions [abstract]
Related party transactions	Related party transactions Members of the Executive Board and Other Executive Members For each of the period presented, the following compensation was granted to the members of the Executive Committee of the Company and were recognized as expense: (in thousands of euro) June 30, 2022 June 30, 2021 Personnel and other short-term employee benefits 1,205 1,881 Extra pension benefits 11 — Share-based compensation 891 538 Executive Board Members and other Executive Members compensation 2,107 2,419 Personnel and other short-term employee benefits correspond to amounts included in personnel expenses for the six-month periods ended June 30, 2022 and 2021 respectively. Members of the Supervisory Board The Company recognized a provision of €176 thousand for attendance fees (jetons de presence) relating to the six months ended June 30, 2022. This amount includes the compensation for the Chairman of the Supervisory Board. Related parties Novo Nordisk A/S is a shareholder, Supervisory Board member and is related to the Company by three licensing agreements related to the drug-candidates lirilumab, monalizumab and avdoralimab. Under the terms of the agreements, Novo Nordisk A/S is eligible to receive milestone payments as well as royalties on future sales. As of June 30, 2022, the Company has no liability to Novo Nordisk A/S. AstraZeneca is a shareholder and is related to the Company through several collaboration and option licensing or license agreements for different drug candidates (monalizumab, avdoralimab, IPH5201 and preclinical molecules) and by a termination and transition agreement relating to the rights of the drug Lumoxiti. The payments between the two companies as well as the liabilities and receivables as of June 30, 2022 are as follows: As of June 30,2022 (in thousands of euro) Payments Assets/Liabilities Collection (AstraZeneca to the Company) / Receivables 48,744 5,691 Payments (the Company to AstraZeneca) / Liabilities (11,535) (5,121) Total 37,209 570 Hervé Brailly is Chairman of the Supervisory Board of the Company and was a member of the Strategy Committee of Mi-mAbs until December 2021. Mi-mAbs is a company with which the Company entered into a framework contract on February 2, 2021 for the provision of services by Mi-mAbs of services in connection with the generation of monoclonal antibodies, the production of monoclonal antibodies or conjugated antibodies, or the in vitro or in vivo pharmacological characterization of potential drug candidates belonging to the Society. The maximum amount paid by the Company under this contract is capped at €600 thousand. The contract was initially concluded on February 2, 2021, with retroactive effect, for a period of one year, from January 1, 2021 to December 31, 2021. It was renewed on December 17, 2021 for a period of one year from from January 1, 2022. An amendment signed in April 4, 2022 modified the maximum amount of the contract, to cap it at €1.0 million for the entire duration of the contract (i.e. years 2021 and 2022). Subsidiaries The business relationships between the Company and its subsidiary are governed by intra-group and commercial agreements, concluded at market standard conditions on an arm’s length basis.

Income _ (loss) per share

Income / (loss) per share	6 Months Ended
	Jun. 30, 2022
Income (Loss) Per Share [Abstract]
Income / (loss) per share	Income / (loss) per share Basic income / (loss) per share Basic income / (loss) per share are calculated by dividing the net earnings attributable to equity holders of the Company by the weighted average number of ordinary shares in issue during the period. June 30, 2022 June 30, 2021 Net income/(loss) 6,303 (23,719) Weighted average number of ordinary shares in circulation 79,753,657 78,997,954 Basic income/(loss) per share (€ per share) 0.08 (0.30) In thousands of euro, except for data share June 30, 2022 June 30, 2021 Net income/(loss) for the period 6,303 (23,719) Weighted average number of ordinary shares in circulation 79,753,657 78,997,954 Adjustment for share instruments 2,132,098 — Diluted income/(loss) per share (€ per share) 0.08 (0.30)

Events after the reporting date

Events after the reporting date	6 Months Ended
	Jun. 30, 2022
Disclosure of non-adjusting events after reporting period [abstract]
Events after the reporting date	Events after the reporting date On August 1, 2022, the Company announced that the combination of monalizumab and cetuximab did not reach the pre-specified efficacy threshold in the protocol-planned interim futility analysis of the Phase 3 INTERLINK-1 clinical study conducted by AstraZeneca. AstraZaneca has thus informed the Company that the study will be discontinued. Consequently, the Company is not eligible for the additional payment of $50.0 million as provided for in the amendment signed in September 2020 relating to the monalizumab collaboration and license agreement entered into with AstraZeneca in 2015. All other development and commercial milestone payments related to the agreement remain unchanged. In August 2022, the Company communicated to Société Générale and BNP Paribas its desire to use the capital repayment extension options of the two State-Guaranteed Loans (“PGE”) contracted in December 2021. As a reminder, the Company had obtained non-dilutive financing of 28.7 million in the form of two PGEs from Société Générale (20.0 million euros) and BNP Paribas (8.7 million euros) with a maturity initial of one year with an option to extend up to five years. Discussions are currently underway with Société Générale and BNP Paribas regarding the conditions for extending repayment and the effective interest rate of l oans. At the date of this report, the Company has obtained agreements in principle from Société Générale and BNP Paribas concerning financing rates after extension option of 1.56% and 0.95% respectively, excluding insurance and guarantee premium with an excess for the whole of 2023.

Basis of presentation and sta_2

Basis of presentation and statement of compliance (Policies)	6 Months Ended
	Jun. 30, 2022
Significant Accounting Policies [Abstract]
Basis of preparation	Basis of preparation The interim condensed consolidated financial statements as of June 30, 2022 and for the six months ended June 30, 2022 and 2021 and the related notes (together, the “interim condensed consolidated financial statements”) have been prepared under the responsibility of the management of the Company in accordance with the underlying assumptions of going concern as the Company’s loss-making situation is explained by the innovative nature of the products developed, therefore involving a multi-year research and development phase. The interim condensed consolidated financial statements were closed by the Executive Board, approved and authorized by the Supervisory Board upon recommendation of the Audit Committee on September 14, 2022. They have been prepared in accordance with IAS 34, ‘Interim Financial Reporting’ as issued by the International Accounting Standard Board (“IASB”). Due to the listing of ordinary shares of the Company on Euronext Paris and in accordance with the European Union’s regulation No. 1606/2002 of July 19, 2002, the interim condensed consolidated financial statements are also prepared in accordance with IFRS, as adopted by the European Union (EU).For the presented periods, the differences between IFRS as issued by IASB and IFRS adopted by EU had no impact on the interim condensed consolidated financial statements. The general accounting conventions were applied in accordance with the underlying assumptions, namely (i) going concern, (ii) permanence of accounting methods from one year to the next and (iii) independence of financial years, and in conformity with the general rules for the preparation and presentation of consolidated financial statements in accordance with International Financial Reporting Standards (“IFRS”). The interim condensed consolidated financial statements do not include all disclosures required for annual financial statements and should therefore be read in conjunction with the consolidated financial statements as of and for the year ended December 31, 2021. The results of the operations for the six months ended June 30, 2022 are not necessarily indicative of the results to be expected for the year ending December 31, 2022 or for any other interim period or for any year in the future. Except for number of shares and per share amounts, all amounts are expressed in thousands of euros, unless stated otherwise. Some amounts may be rounded for the calculation of financial information contained in the interim condensed consolidated financial statements. Accordingly, the totals in some tables may not be the exact sum of the preceding figures.
Use of judgments and estimates	Use of judgments and estimates The preparation of financial statements in accordance with IFRS requires the Company to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expenses during the reporting period. These estimates can be revised where the circumstances on which they are based change. The actual results may therefore differ from the estimates initially formulated. The estimates and judgments which are mainly used by the Company are detailed in note 18.1.1 in paragraph 2.w) of the appendix to the consolidated financial statements as of December 31, 2021 of the Universal Registration Document published on April 24, 2022. Estimates and judgments which impact the condensed consolidated financial statements at June 30, 2022 are: • accounting for collaboration and licensing agreements (note 6 and 13); • estimate of the recoverable amount of the acquired and under progress licenses (note 6); • estimate of the useful life of the acquired licenses (note 6).
Recently issued accounting standards and interpretations	Recently issued accounting standards and interpretations Application of the following amended standards is mandatory for the first time for the financial period beginning on January 1, 2022 and, as such, they have been adopted by the Company: • Amendments to IAS 16: Property, Plant and Equipment • Amendments to IAS 37 : Provisions, Contingent Liabilities and Contingent Assets Those amended standards have no impact on the interim condensed consolidated financial statements.
Translation of transactions denominated in foreign currency	Translation of transactions denominated in foreign currency Foreign currency transactions are translated into the presentation currency using the following exchange rates: June 30, 2021 December 31, 2021 June 30, 2022 €1 equals to Average rate Closing rate Average rate Closing rate Average rate Closing rate USD 1.2053 1.1824 1.1827 1.1326 1.0933 1.0387

Basis of presentation and sta_3

Basis of presentation and statement of compliance (Tables)	6 Months Ended
	Jun. 30, 2022
Significant Accounting Policies [Abstract]
Disclosure of effect of changes in foreign exchange rates	Foreign currency transactions are translated into the presentation currency using the following exchange rates: June 30, 2021 December 31, 2021 June 30, 2022 €1 equals to Average rate Closing rate Average rate Closing rate Average rate Closing rate USD 1.2053 1.1824 1.1827 1.1326 1.0933 1.0387

Cash, cash equivalents, short_2

Cash, cash equivalents, short-term investments and non-current financial assets (Tables)	6 Months Ended
	Jun. 30, 2022
Subclassifications of assets, liabilities and equities [abstract]
Disclosure of cash, cash equivalents and financial assets	(in thousands of euro) June 30, 2022 December 31, 2021 Cash and cash equivalents 102,949 103,756 Short-term investments 20,401 16,080 Cash, cash equivalents and short-term investments 123,350 119,836 Non-current financial assets 34,806 39,878 Cash, cash equivalents and financial assets 158,156 159,714
Disclosure of reconciliation of changes in short-term investments and non-current financial assets	Changes in short-term investments and non-current financial assets for the six months ended June 30, 2021 and 2022 are the following: (in thousands of euro) December 31, 2021 Additions (1) Deductions (2) Variance of fair value through the consolidated statement of income (loss) Variation of accrued interests Foreign currency effect June 30, 2022 Short-term investments 16,080 2,935 — 53 — 1,333 20,401 Non-current financial assets 39,878 — (2,935) (2,308) 172 — 34,806 Total 55,958 2,935 (2,935) (2,255) 172 1,333 55,207 (in thousands of euro) December 31, 2020 Additions Deductions Variance of fair value through the consolidated statement of income (loss) Variation of accrued interests Foreign currency effect June 30, 2021 Short-term investments 14,845 — — 53 — 443 15,341 Non-current financial assets 38,934 — — 978 170 — 40,083 Total 53,779 — — 1,031 170 443 55,424 (1) The additions correspond to both acquisitions and reclassifications of financial assets according to their maturity at the closing date .

Trade receivables and others (T

Trade receivables and others (Tables)	6 Months Ended
	Jun. 30, 2022
Subclassifications of assets, liabilities and equities [abstract]
Disclosure of trade receivables and others	(in thousands of euro) June 30, 2022 December 31, 2021 Other receivables 78 814 Research tax credit(1) 31,309 10,310 Other tax credits 333 333 Prepaid expenses 3,688 2,582 VAT refund 1,545 1,170 Trade account receivables (2) 8,565 846 Prepayments made to suppliers 2,929 2,364 Receivables and others 48,447 18,420 Research tax credit(1) 13,084 29,821 Receivables and others - non-current 13,084 29,821 Trade receivables and others 61,531 48,241 (1) The Research tax credit is recognized as other operating income in the year to which the eligible research expenditure relates. The amount of €13,084 thousand recognized in non-current receivables corresponds to the CIR for the 2020 tax year following the fact that the Company no longer meets the eligibility criteria for the SME status as of December 31, 2019. As of December 31, 2020 and 2021 respectively, the Company has ensured that the eligibility criteria for the SME status are met again. The Company is therefore eligible for the early repayment by the French treasury during the fiscal year 2022 of the 2021 Research Tax Credit for an amount of €10,302 thousand. This amount has not yet been received by the Company as of June 30, 2022 and is classified as current receivable in the same way as the CIR for the 2019 tax year, for an amount of €16,737 thousand, and the first half of 2022 for an amount of €4,270 thousand.

Intangible assets (Tables)

Intangible assets (Tables)	6 Months Ended
	Jun. 30, 2022
Intangible assets other than goodwill [abstract]
Disclosure of detailed information about intangible assets	(in thousands of euro) Purchased licenses Other intangible assets In progress Total January 1, 2021 5,103 185 41,000 46,289 Acquisitions — 13 — 13 Additional considerations — — — — Disposals — — — — Amortizations (1,039) (1) (70) — (1,109) Transfers — — — — June 30, 2021 4,064 128 41,000 45,193 January 1, 2022 3,161 29 41,000 44,192 Acquisitions — — — — Additional considerations — — — — Disposals — — — — Amortizations (940) (1) — — (940) Transfers — — — — June 30, 2022 2,221 29 41,000 43,260

Property and equipment (Tables)

Property and equipment (Tables)	6 Months Ended
	Jun. 30, 2022
Property, plant and equipment [abstract]
Disclosure of detailed information about property, plant and equipment	(in thousands of euro) Lands and buildings Laboratory equipment and other In progress Total Of which finannce leases January 1, 2021 5,751 5,576 367 11,694 6,423 Acquisitions — 260 — 260 — Disposals — (2) — (2) — Depreciation (393) (668) — (1,061) (535) Transfers — 4 (4) — — June 30, 2021 5,358 5,170 363 10,891 5,888 (in thousands of euro) Lands and buildings Laboratory equipment and other In progress Total Of which right of use assets(3) January 1, 2022 4,981 5,187 6 10,174 5,342 Acquisitions 14 458 — 472 — Disposals — — — — — Depreciation (379) (711) — (1,090) (534) Transfers — — — — — June 30, 2022 4,616 4,934 6 9,556 4,808

Trade payables and others (Tabl

Trade payables and others (Tables)	6 Months Ended
	Jun. 30, 2022
Subclassifications of assets, liabilities and equities [abstract]
Disclosure of trade payables and others	(in thousands of euro) June 30, 2022 December 31, 2021 Suppliers (excluding payables related to capital expenditures) 12,924 14,729 Tax and employee-related payables 5,478 7,463 Other payables 13 6,380 Trade payables and others (excluding payables related to capital expenditures) 18,415 28,573 Payables related to capital expenditures 252 — Payables and others 18,667 28,573

Financial liabilities (Tables)

Financial liabilities (Tables)	6 Months Ended
	Jun. 30, 2022
Subclassifications of assets, liabilities and equities [abstract]
Disclosure of financial liabilities per maturity	(in thousands of euro) December 31, 2021 Proceeds from borrowing Proceeds from lease liabilities and other non cash effects Repayments of borrowings/leases liabilities Exchange rate variation (non cash) June 30, 2022 State guaranteed loan Société Générale (1) 20,000 — 50 — — 20,050 State guaranteed loan BNP Paribas (1) 8,700 — 22 — — 8,722 Lease liabilities – Building "Le Virage" 1,875 — — (260) — 1,614 Lease liabilities – Premises Innate Inc. 391 — 45 (44) 5 396 Lease liabilities – Laboratory equipment 464 — — (87) — 376 Lease liabilities – Vehicles 53 — 38 (19) — 71 Lease liabilities - Printers 35 — — (4) — 31 Borrowing – Equipment 209 — — (27) — 181 Borrowing – Building 12,525 — — (591) — 11,933 Total 44,252 — 155 (1,032) 5 43,374 (in thousands of euro) December 31, 2020 Proceeds from borrowing Proceeds from lease liabilities (non cash) Repayments of borrowings/leases liabilities Exchange rate variation (non cash) June 30, 2021 BPI PTZI IPH41 150 — — (150) — — Lease liabilities – Real estate property 1,454 — (1,454) — — — Lease liabilities – Building "Le Virage" 2,387 — — (255) — 2,131 Lease liabilities – Premises Innate Inc. 447 — — (18) (5) 423 Lease liabilities – Laboratory equipment 639 — — (87) — 551 Lease liabilities – Vehicles 21 — — (6) — 14 Lease liabilities - Printers 41 — — (2) — 39 Borrowing – Equipment 262 — — (25) — 236 Borrowing – Building 13,687 — — (579) — 13,107 Total 19,087 — (1,454) (1,121) (5) 16,502 (1) On January 5, 2022, the Company announced that it had obtained €28.7 million in non-dilutive financing in the form of two State Guaranteed Loans from Société Générale (€20.0 million) and BNP Paribas (€8.7 million). The Company received the funds related to these two loans on December 27 and 30, 2021 respectively. Both loans have an initial maturity of one year with an option to extend to five years usable from August, 2022. They are 90% guaranteed by the French government as part of the package of measures put in place by the French government to support companies during the COVID-19 pandemic. As of June 30, 2022, the Company was not able to use the options to extend the principal repayment of these loans. Thus, at the same date, the effective interest rate applied to these contracts is 0.5% which is the contractual rate for repayment within one year. In August 2022, the Company communicated to Société Générale and BNP Paribas its desire to use the capital repayment extension options of the two State-Guaranteed Loans (“PGE”) contracted in December 2021 (see note 21).
Disclosure of maturity analysis for non-derivative financial liabilities	The table below shows the schedule for the contractual repayment of financial liabilities (being principal and interest payments) as of June 30, 2022: (in thousands of euro) Within 1 year From 2nd to 5th year included Over 5 years Total State guaranteed loan Société Générale 20,050 — — 20,050 State guaranteed loan BNP Paribas 8,722 — — 8,722 Lease liabilities – Building "Le Virage" 527 1,088 — 1,614 Lease liabilities – Premises Innate Inc. 91 299 — 396 Lease liabilities – Laboratory equipment 178 199 — 376 Lease liabilities – Vehicles 29 44 — 71 Lease liabilities - Printers 9 22 — 31 Borrowing – Equipment 55 126 — 181 Borrowing – Building 1,198 5,039 5,697 11,933 Total financial liabilities 30,859 6,817 5,697 43,374

Employee benefit (Tables)

Employee benefit (Tables)	6 Months Ended
	Jun. 30, 2022
Disclosure of information about defined benefit plans [abstract]
Disclosure of defined benefit plans	Defined benefit obligation (in thousands of euro) June 30, 2022 December 31, 2021 Allowance for retirement defined benefit 2,306 2,544 Allowance for seniority awards 390 432 Defined benefit obligations 2,696 2,975
Disclosure of net defined benefit liability (asset)	Amounts recognized in the statement of financial position are determined as follows (in thousand euros): As of January 1, 2021 4,177 IAS19 Restatement related to change in calculation method - IFRIC (1) (1,054) As of January 1, 2021 Restated 3,123 Service cost 484 Interest costs (47) Actuarial (gain) / loss (584) As of December 31, 2021 2,976 Service cost 205 Interest costs (14) Actuarial (gain) / loss (471) As of June 30, 2022 2,696

Capital (Tables)

Capital (Tables)	6 Months Ended
	Jun. 30, 2022
Share Capital and Share Base Payments [Abstract]
Disclosure of number and weighted average exercise prices of other equity instruments	The Company has issued BSAs, BSAARs, AGAs and AGAPs as follows: Date Types Number of warrants issued as of 6/30/2022 Number of warrants void as of 6/30/2022 Number of warrants exercised as of 6/30/2022 Number of warrants outstanding as of 6/30/2022 Maximum number of shares to be issued as of 6/30/2022 Exercise price per share (in €) Sept. 9, 2011 BSAAR 2011 650,000 25,000 625,000 — — 2.04 May 27, 2013 BSAAR 2012 146,050 — 86,700 59,350 59,350 2.04 July 1, 2015 BSAAR 2015 1,050,382 2,720 1,940 1,045,722 1,045,722 7.20 October 21, 2016 AGAP Management 2016-1 2,000 550 250 86,700 59,350 59,350.00 October 21, 2016 AGAP Employees 2016-1 2,486 251 167 2,068 268,840 - October 21, 2016 AGA Management 2016-1 50,000 — 50,000 — — - December 30, 2016 AGAP Management 2016-2 3,000 — — 3,000 333,000 - December 30, 2016 AGA Management 2016-2 250,000 — 250,000 — — - April 3,2018 AGAP Employees 2017-1 5,725 5,725 — — — - April 3,2018 AGAP Management 2017-1 2,400 2,400 — — — — April 3,2018 AGA Employees 2017 114,500 4,000 110,500 — — — July 3, 2018 AGA Bonus 2018-1 67,028 469 66,559 — — - November 20, 2018 AGAP Perf Employees 2018-1 327,500 224,375 103,125 — — - November 20, 2018 AGAP Perf Management 2018-1 260,000 150,000 110,000 — — - January 14, 2019 AGA Employees 2018 90,650 5,000 85,650 — — - April 29, 2019 AGA New Members 2017-1 25,000 — 25,000 — — - July 3, 2019 AGA Bonus 2019-1 57,376 — 57,376 — — - July 13, 2020 AGA Bonus 2020-1 79,861 17,885 48,362 13,614 13,614 - August 5, 2020 AGAP Employees 2020-1 766,650 269,282 — 497,368 497,368 - August 5, 2020 AGAP Management 2020-1 710,000 60,000 — 650,000 650,000 - July 22, 2021 AGA Bonus 2021-1 125,748 — — 125,748 125,748 - October 1, 2021 AGAP Employees 2021-1 1,066,600 67,800 — 998,800 998,800 - October 1, 2021 AGAP Management 2021-1 610,000 90,000 — 520,000 520,000 - July 21, 2020 Stock Options 2020-1 102,000 102,000 — — — - November 4, 2019 AGAP 2019 Employees 2019 546,700 202,400 — 344,300 344,300 - November 4, 2019 AGAP 2019 Management 2019 355,000 60,000 — 295,000 295,000 - July 29, 2011 BSA 2011-2 225,000 25,000 200,000 — — 1.77 July 17, 2013 BSA 2013 237,500 — 191,140 46,360 46,360 2.36 July 16, 2014 BSA 2014 150,000 — 75,000 75,000 75,000 8.65 April 27, 2015 BSA 2015-1 70,000 — — 70,000 70,000 9.59 July 1, 2015 BSA 2015-2 14,200 — — 14,200 14,200 14.05 September 20, 2017 BSA 2017 37,000 — — 37,000 37,000 11.00 Total as of June 30, 2022 8,200,356 1,314,857 2,061,019 4,824,480 5,576,052

Financial instruments recogni_2

Financial instruments recognized in the statement of financial position and related effect on the income statement (Tables)	6 Months Ended
	Jun. 30, 2022
Disclosure of detailed information about financial instruments [abstract]
Disclosure of detailed information about financial instruments	The following tables show the carrying amounts and fair values of financial assets and financial liabilities. The tables do not include fair value information for financial assets and financial liabilities not measured at fair value if the carrying amount is a reasonable approximation of fair value. As of June 30, 2022 Book value on the statement of financial position Fair value through profit and loss (1) Amortized cost (2) Fair value Financial assets Non-current financial assets 34,806 34,806 — 34,806 Trade receivables and others 61,531 — 61,531 61,531 Short-term investments 20,401 20,401 — 20,401 Cash and cash equivalents 102,949 102,949 — 102,949 Total financial assets 219,687 158,156 61,531 219,687 Financial liabilities Financial liabilities—non-current portion 12,523 — 12,523 12,523 Financial liabilities—current portion 30,851 — 30,851 30,851 Trade payables and others 18,667 — 18,667 18,667 Total financial liabilities 62,041 — 62,041 62,041 As of December 31, 2021 Book value on the statement of financial position Fair value through profit and loss (1) Amortized Cost (2) Fair value Financial assets Non-current financial assets 39,878 39,878 — 39,878 Trade receivables and others 48,241 — 48,241 48,241 Short-term investments 16,080 16,080 — 16,080 Cash and cash equivalents 103,756 103,756 — 103,756 Total financial assets 207,955 159,714 48,241 207,955 Financial liabilities Financial liabilities—non-current portion 13,503 — 13,503 13,503 Financial liabilities—current portion 30,748 — 30,748 30,748 Trade payables and others 28,573 — 28,573 28,573 Total financial liabilities 72,824 — 72,824 72,824 ( 1) The fair value of financial assets classified as fair value through profit and loss corresponds to the market value of the assets, which are primarily determined using level 2 measurements. (2) The book amount of financial assets and liabilities measured at amortized cost was deemed to be a reasonable estimation of fair value.

Revenue, government financing_2

Revenue, government financing for research expenditures and sales (Tables)	6 Months Ended
	Jun. 30, 2022
Disclosure of disaggregation of revenue from contracts with customers [abstract]
Disclosure of revenue from collaboration and licensing agreements	Revenues from collaboration and licensing agreements result from agreements signed with AstraZeneca and Sanofi : (in thousands of euro) June 30, 2022 June 30, 2021 Proceeds from collaboration and licensing agreements 41,919 7,095 of which monalizumab agreement (AstraZeneca) 16,440 6,095 of which IPH5201 agreement (AstraZeneca) 4,826 — of which preclinical molecules agreement (AstraZeneca) 17,400 — of which Sanofi agreement 3,000 1,000 of which other agreements 252 — Invoicing of R&D costs (IPH5201 and advoralimab agreements) (21) 1,209 Exchange gains or losses on collaboration agreement (627) — Revenue from collaboration and licensing agreements 41,271 8,304
Disclosure of change in deferred revenue and collaboration liabilities	Change in deferred revenue relating to monalizumab agreement: (in thousands of euro) Total As of December 31, 2020 26,572 Revenue for the six months ended June 30, 2021 (6,095) Transfer from / (to) collaboration liabilities 188 As of June 30, 2021 20,665 As of December 31, 2021 20,159 Increase in deffered revenu resulting from the $50m milestone relating to the dosage of the first patent in the Phase 3 trial PACIFIC-9 47,687 Revenue for the six months ended June 30, 2022 (16,440) Transfer from / (to) collaboration liabilities (34,094) As of June 30, 2022 17,312 (1) The increase in deferred revenue relating to monalizumab agreement between December 31, 2021 and June 30, 2022 is explained by the additional payment of €47,687 thousand ($50,000 thousand) made by AstraZeneca in June 2022 and triggered by the launch of the “PACIFIC-9” Phase 3 trial on April 28, 2022. This increase has led to a simultaneous increase in collaboration commitment ("collaboration liability"- see below) of €34,335 thousand ($36,000 thousand) in accordance with the Company’s July 2019 option concerning the co-financing of Phase 3 trials in the field of collaboration. Change in collaboration liabilities relating to monalizumab agreement: (in thousands of euro) Total As of December 31, 2020 46,686 Revenue for the six months ended Additions 1,501 Deductions (2,253) As of June 30, 2021 45,934 As of December 31, 2021 40,415 Revenue for the six months ended Additions (1) 38,568 Deductions (5,862) As of June 30, 2022 73,121 Change in deferred revenue relating to the 2018 future programs option agreement (in thousands of euro) Total As of December 31, 2021 17,400 Augmentation — Deductions (17,400) As of June 30, 2022 —
Disclosure of variance of deferred revenue	Schedule of variance of deferred revenue (in thousands of euro) As of December 31, 2021 Recognition in P&L Proceeds Transfer from / (to) collaboration liabilities As of June 30, 2022 Monalizumab 20,159 (16,440) 47,687 (34,094) 17,310 IPH5201 — — — — — Preclinical molecules 17,400 (17,400) — — — Others 353 (235) — — 117 Total 37,912 (34,075) 47,687 (34,094) 17,427 (in thousands of euro) As of December 31, 2020 Recognition in P&L Proceeds Transfer from / (to) collaboration liabilities As of June 30, 2021 Monalizumab 26,572 (6,095) — 188 20,665 IPH5201 — — — — — Preclinical molecules 17,400 — — — 17,400 Total 43,973 (6,095) — 188 38,066
Disclosure of government financing for research expenditures	The total amount for government financing for research expenditures recorded as other income in the income statement can be analysed as follows: (in thousands of euro) June 30, 2022 June 30, 2021 Research tax credit 4,270 4,933 Grant 49 1,435 Government financing for research expenditures 4,319 6,368

Operating expenses (Tables)

Operating expenses (Tables)	6 Months Ended
	Jun. 30, 2022
Analysis of income and expense [abstract]
Disclosure of expenses by nature	Operating expenses (in thousands of euro) June 30, 2022 June 30, 2021 (1) R&D G&A Total R&D G&A Total Subcontracting costs(2) (10,727) — (10,727) (10,179) (13) (10,193) Cost of supplies and consumable materials (1,663) (285) (1,948) (1,513) (666) (2,180) Personnel expenses other than share-based compensation (7,447) (4,448) (11,895) (6,827) (4,573) (11,400) Share-based compensation (1,275) (1,321) (2,596) (219) (633) (852) Personnel expenses (8,722) (5,769) (14,491) (7,046) (5,206) (12,252) Non-scientific advisory and consulting(3) (752) (2,242) (2,994) (175) (2,501) (2,676) Leasing and maintenance (97) (961) (1,058) (131) (1,017) (1,148) Travel expenses and meeting attendance (245) (109) (354) (22) (36) (58) Marketing, communication and public relations (84) (375) (459) (44) (115) (159) Scientific advisory and consulting(4) (360) — (360) 4 (83) (79) Other purchases and external expenses (9) (1,123) (1,132) — (1,255) (1,255) Depreciation and amortization (1,274) (768) (2,042) (1,473) (689) (2,161) Intellectual property expenses (492) (176) (668) (779) (20) (798) Other income and (expenses), net (531) (332) (863) 151 (1,043) (892) Total operating expenses (24,956) (12,140) (37,096) (21,208) (12,643) (33,851) (1) Items relating to the six months ended June 30, 2021 have been restated to reflect the impact of the classification of Lumoxiti's activities as discontinued operations in 2021. These items are presented in note 17. (2) The Company subcontracts a significant part of its pre-clinical (pharmaceutical development, tolerance studies and other model experiments, etc.) and clinical operations (coordination of trials, hospital costs, etc.) to third parties. (3) Non-scientific advisory and consulting are services performed to support the general and administration activities of the Company, such as legal, accounting and audit fees as well as business development support. (4) Scientific advisory and consulting expenses relate to consulting services performed by third parties to support the research and development activities of the Company.

Net financial income _ (loss) (

Net financial income / (loss) (Tables)	6 Months Ended
	Jun. 30, 2022
Analysis of income and expense [abstract]
Disclosure of net financial income (loss)	Net financial income (loss) can be analyzed as follows : (in thousands of euro) June 30, 2022 June 30, 2021 Interests on financial assets 198 171 Change in valuation allowance on financial instruments 53 1,040 Foreign exchange gains 3,797 2,185 Other financial income — 94 Financial income 4,048 3,490 Foreign exchange losses (3,663) (1,602) Unrealized losses on financial assets (2,309) — Interest on financial liabilities (194) (160) Other financial expenses — (18) Financial expenses (6,166) (1,781) Net financial income (loss) (2,118) 1,709

Discontinued Operations (Tables

Discontinued Operations (Tables)	6 Months Ended
	Jun. 30, 2022
Discontinued Operations [Abstract]
Disclosure of analysis of financial performance and cash-flows from discontinued operations	a) Financial Performance (in thousands of euro) June 30, 2022 June 30, 2021 Revenue and other income Revenue from collaboration and licensing agreements — — Sales 42 1,015 Total revenue and other income 42 1,015 Operating expenses Research and development expenses (11) (586) Selling, general and administrative expenses (104) (6,678) Impairment of intangible assets — — Total operating expenses (115) (7,264) Net income (loss) from distribution agreements — — Operating income (loss) (73) (6,249) Financial income — — Financial expenses — — Net financial income (loss) — — Net income (loss) before tax (73) (6,249) Income tax expense — — Net income (loss) from discontinued operations (73) (6,249) b) Cash-Flows (in thousands of euro) June 30, 2022 June 30, 2021 Net cash generated from / (used in) operating activities (5,539) (4,398) Net cash generated from / (used in) investing activities — — Net cash generated from / (used in) financing activities — — Net cash flows from discontinued operations (5,539) (4,398)

Related party transactions (Tab

Related party transactions (Tables)	6 Months Ended
	Jun. 30, 2022
Related party transactions [abstract]
Disclosure of key management personnel compensation	For each of the period presented, the following compensation was granted to the members of the Executive Committee of the Company and were recognized as expense: (in thousands of euro) June 30, 2022 June 30, 2021 Personnel and other short-term employee benefits 1,205 1,881 Extra pension benefits 11 — Share-based compensation 891 538 Executive Board Members and other Executive Members compensation 2,107 2,419
Disclosure of transactions between related parties	The payments between the two companies as well as the liabilities and receivables as of June 30, 2022 are as follows: As of June 30,2022 (in thousands of euro) Payments Assets/Liabilities Collection (AstraZeneca to the Company) / Receivables 48,744 5,691 Payments (the Company to AstraZeneca) / Liabilities (11,535) (5,121) Total 37,209 570

Income _ (loss) per share (Tabl

Income / (loss) per share (Tables)	6 Months Ended
	Jun. 30, 2022
Income (Loss) Per Share [Abstract]
Summary of income (loss) per share	Basic income / (loss) per share are calculated by dividing the net earnings attributable to equity holders of the Company by the weighted average number of ordinary shares in issue during the period. June 30, 2022 June 30, 2021 Net income/(loss) 6,303 (23,719) Weighted average number of ordinary shares in circulation 79,753,657 78,997,954 Basic income/(loss) per share (€ per share) 0.08 (0.30) In thousands of euro, except for data share June 30, 2022 June 30, 2021 Net income/(loss) for the period 6,303 (23,719) Weighted average number of ordinary shares in circulation 79,753,657 78,997,954 Adjustment for share instruments 2,132,098 — Diluted income/(loss) per share (€ per share) 0.08 (0.30)

The Company and key events - Th

The Company and key events - The company (Details) € in Thousands	6 Months Ended
	Jun. 30, 2022 EUR (€) employee subsidiary	Jun. 30, 2021 EUR (€) employee		Dec. 31, 2021 EUR (€)	Dec. 31, 2020 EUR (€)
Company Information [Abstract]
Net income for the period	€ 6,303	€ (23,719)	[1]
Total shareholders’ equity	€ 116,333	€ 133,561		€ 107,440	€ 155,976
Number of subsidiaries | subsidiary	1
Number of employees | employee	213	212
[1]Comparative relating to the six months ended June 30, 2021 have been restated to reflect the impact of the classification of Lumoxiti's activities as discontinued operations in 2021. See note 17 of the interim condensed consolidated financial statements as of June 30, 2022.

The Company and key events - Ke

The Company and key events - Key events for the six-month period ended June 30, 2022 (Details) € in Thousands, $ in Thousands					6 Months Ended
	Aug. 02, 2022 EUR (€)	Jun. 17, 2022 EUR (€)	Jun. 17, 2022 USD ($)	Jun. 01, 2022 USD ($)	Jun. 30, 2022 EUR (€) program	Jun. 30, 2022 USD ($) program	Jun. 30, 2021 EUR (€)		Jun. 02, 2022 program
Disclosure of disaggregation of revenue from contracts with customers [line items]
Revenue from collaboration and licensing agreements					€ 41,271		€ 8,304	[1]
2015 monalizumab agreement, with AstraZeneca
Disclosure of disaggregation of revenue from contracts with customers [line items]
Milestone payment received		€ 47,687	$ 50,000
IPH5201 agreement, with AstraZeneca
Disclosure of disaggregation of revenue from contracts with customers [line items]
Collaboration milestone payments receivable | $				$ 5,000
Revenue from collaboration and licensing agreements					€ 4,826		0
IPH5201 agreement, with AstraZeneca | Major milestone payment received
Disclosure of disaggregation of revenue from contracts with customers [line items]
Milestone payment received	€ 4,900
IPH43, IPH25, IPH26 and IPH62, with AstraZeneca
Disclosure of disaggregation of revenue from contracts with customers [line items]
Number of underlying programs terminated | program					4	4			4
Revenue from collaboration and licensing agreements					€ 17,400	$ 20,000
IPH6101 agreement, with Sanofi
Disclosure of disaggregation of revenue from contracts with customers [line items]
Milestone payment received					3,000
Revenue from collaboration and licensing agreements					€ 3,000		€ 1,000
[1]Comparative relating to the six months ended June 30, 2021 have been restated to reflect the impact of the classification of Lumoxiti's activities as discontinued operations in 2021. See note 17 of the interim condensed consolidated financial statements as of June 30, 2022.

Basis of presentation and sta_4

Basis of presentation and statement of compliance (Details)	6 Months Ended		12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021
Significant Accounting Policies [Abstract]
Average rate (€1 equals to USD)	1.0933	1.2053	1.1827
Closing rate (€1 equals to USD)	1.0387	1.1824	1.1326

Cash, cash equivalents, short_3

Cash, cash equivalents, short-term investments and non-current financial assets - Disclosure of cash, cash equivalents and financial assets (Details) - EUR (€) € in Thousands	Jun. 30, 2022	Dec. 31, 2021	Jun. 30, 2021	Dec. 31, 2020
Subclassifications of assets, liabilities and equities [abstract]
Cash and cash equivalents	€ 102,949	€ 103,756	€ 103,980	€ 136,792
Short-term investments	20,401	16,080
Cash, cash equivalents and short-term investments	123,350	119,836
Non-current financial assets	34,806	39,878	€ 40,083	€ 38,934
Cash, cash equivalents and financial assets	€ 158,156	€ 159,714

Cash, cash equivalents, short_4

Cash, cash equivalents, short-term investments and non-current financial assets - Additional Information (Details) € in Thousands	6 Months Ended
	Jun. 30, 2022 EUR (€) Rate shares	Jun. 30, 2021 EUR (€)	Dec. 31, 2021 EUR (€)
Disclosure of financial assets [Line Items]
Cash, cash equivalents and financial assets	€ 158,156		€ 159,714
Non-current financial assets, variation of fair value through the consolidated statement of income (loss)	(2,308)	€ 978
Short-term investments, variation of fair value through the consolidated statement of income (loss)	€ 53	€ 53
SICAV
Disclosure of financial assets [Line Items]
Number of SICAV held | shares	7
SICAV and mutual funds | Minimum
Disclosure of financial assets [Line Items]
Risk profile rate | Rate	1
SICAV and mutual funds | Maximum
Disclosure of financial assets [Line Items]
Risk profile rate | Rate	7
Cash, cash equivalents, and financial assets denominated in US dollars
Disclosure of financial assets [Line Items]
Cash, cash equivalents and financial assets	€ 42,505		€ 47,164

Cash, cash equivalents, short_5

Cash, cash equivalents, short-term investments and non-current financial assets - Disclosure of reconciliation of changes in short-term investments and non-current financial assets (Details) - EUR (€) € in Thousands	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Subclassifications of assets, liabilities and equities [abstract]
Beginning balance, current investments	€ 16,080	€ 14,845
Short-term investments, acquisitions	2,935	0
Short-term investments, disposals	0	0
Short-term investments, variation of fair value through the consolidated statement of income (loss)	53	53
Short-term investments, variation of accrued interest	0	0
Short-term investments, foreign currency effect	1,333	443
Ending balance, current investments	20,401	15,341
Beginning balance, non-current financial assets	39,878	38,934
Non-current financial assets, acquisitions	0	0
Non-current financial assets, disposals	(2,935)	0
Non-current financial assets, variation of fair value through the consolidated statement of income (loss)	(2,308)	978
Non-current financial assets, variation of accrued interest	172	170
Non-current financial assets, foreign currency effect	0	0
Ending balance, non-current financial assets	34,806	40,083
Beginning balance, total	55,958	53,779
Total, acquisitions	2,935	0
Total, disposals	(2,935)	0
Total, variation of fair value through the consolidated statement of income (loss)	(2,255)	1,031
Total variance of accrued interest	172	170
Total, foreign currency effect	1,333	443
Ending balance, total	€ 55,207	€ 55,424

Trade receivables and others (D

Trade receivables and others (Details) - EUR (€) € in Thousands	Jun. 30, 2022	Dec. 31, 2021
Disclosure of financial assets [Line Items]
Other receivables	€ 78	€ 814
Research tax credit	31,309	10,310
Other tax credits	333	333
Prepaid expenses	3,688	2,582
VAT refund	1,545	1,170
Trade account receivables	8,565	846
Prepayments made to suppliers	2,929	2,364
Receivables and others	48,447	18,420
Research tax credit	13,084	29,821
Receivables and others - non-current	13,084	29,821
Trade receivables and others	61,531	€ 48,241
Research tax credit 2020	13,084
Research tax credit 2021	10,302
Research tax credit 2019	16,737
Research tax credit, first six months 2022	4,270
IPH5201 agreement, with AstraZeneca
Disclosure of financial assets [Line Items]
Trade account receivables	4,676
IPH6101 agreement, with Sanofi
Disclosure of financial assets [Line Items]
Trade account receivables	€ 3,000

Intangible assets - Disclosure

Intangible assets - Disclosure of detailed information about intangible assets (Details) - EUR (€) € in Thousands	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Disclosure of detailed information about intangible assets [line items]
Intangible assets other than goodwill at beginning of period	€ 44,192	€ 46,289
Acquisitions	0	13
Additional considerations	0	0
Disposals	0	0
Amortizations	(940)	(1,109)
Transfers	0	0
Intangible assets other than goodwill at end of period	43,260	45,193
Monalizumab agreement
Disclosure of detailed information about intangible assets [line items]
Amortizations	(903)
Purchased licenses
Disclosure of detailed information about intangible assets [line items]
Intangible assets other than goodwill at beginning of period	3,161	5,103
Acquisitions	0	0
Additional considerations	0	0
Disposals	0	0
Amortizations	(940)	(1,039)
Transfers	0	0
Intangible assets other than goodwill at end of period	2,221	4,064
Other intangible assets
Disclosure of detailed information about intangible assets [line items]
Intangible assets other than goodwill at beginning of period	29	185
Acquisitions	0	13
Additional considerations	0	0
Disposals	0	0
Amortizations	0	(70)
Transfers	0	0
Intangible assets other than goodwill at end of period	29	128
In progress
Disclosure of detailed information about intangible assets [line items]
Intangible assets other than goodwill at beginning of period	41,000	41,000
Acquisitions	0	0
Additional considerations	0	0
Disposals	0	0
Amortizations	0	0
Transfers	0	0
Intangible assets other than goodwill at end of period	€ 41,000	€ 41,000

Intangible assets - Additional

Intangible assets - Additional Information (Details) - EUR (€)	1 Months Ended		47 Months Ended
	Jan. 31, 2022	Oct. 31, 2020	Jun. 30, 2022	Dec. 31, 2021	Jun. 30, 2021	Dec. 31, 2020	Jul. 31, 2017
Disclosure of detailed information about intangible assets [line items]
Intangible assets other than goodwill			€ 43,260,000	€ 44,192,000	€ 45,193,000	€ 46,289,000
Financial liabilities			43,374,000	44,252,000	€ 16,502,000	€ 19,087,000
2014 Monalizumab (NKG2A) agreement with Novo Nordisk
Disclosure of detailed information about intangible assets [line items]
Intangible assets other than goodwill			2,252,000	€ 3,155,000
IPH5201 (anti-CD39) rights acquired from Orega Biotech
Disclosure of detailed information about intangible assets [line items]
Payments for milestone	€ 400,000
IPH5401 (anti-C5aR) rights acquired from Novo Nordisk A/S
Disclosure of detailed information about intangible assets [line items]
Intangible assets other than goodwill							€ 40,000,000
Payments for milestone		€ 1,000,000
Impairment of intangible assets			0
Financial liabilities			€ 0
Discount rate used in current measurement of fair value less costs of disposal			11%

Property and equipment (Details

Property and equipment (Details) - EUR (€) € in Thousands	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Disclosure of detailed information about property, plant and equipment [Line Items]
Property, plant and equipment at beginning of period	€ 10,174	€ 11,694
Acquisitions	472	260
Disposals	0	(2)
Depreciation	(1,090)	(1,061)
Transfers	0	0
Property, plant and equipment at end of period	9,556	10,891
Assets under finance-lease agreements
Disclosure of detailed information about property, plant and equipment [Line Items]
Property, plant and equipment at beginning of period		6,423
Acquisitions		0
Disposals		0
Depreciation		(535)
Transfers		0
Property, plant and equipment at end of period		5,888
Right-of-use assets
Disclosure of detailed information about property, plant and equipment [Line Items]
Property, plant and equipment at beginning of period	5,342
Acquisitions	0
Disposals	0
Depreciation	(534)
Transfers	0
Property, plant and equipment at end of period	4,808
Lands and buildings
Disclosure of detailed information about property, plant and equipment [Line Items]
Property, plant and equipment at beginning of period	4,981	5,751
Acquisitions	14	0
Disposals	0	0
Depreciation	(379)	(393)
Transfers	0	0
Property, plant and equipment at end of period	4,616	5,358
Laboratory equipment and other
Disclosure of detailed information about property, plant and equipment [Line Items]
Property, plant and equipment at beginning of period	5,187	5,576
Acquisitions	458	260
Disposals	0	(2)
Depreciation	(711)	(668)
Transfers	0	4
Property, plant and equipment at end of period	4,934	5,170
In progress
Disclosure of detailed information about property, plant and equipment [Line Items]
Property, plant and equipment at beginning of period	6	367
Acquisitions	0	0
Disposals	0	0
Depreciation	0	0
Transfers	0	(4)
Property, plant and equipment at end of period	€ 6	€ 363

Trade payables and others (Deta

Trade payables and others (Details) - EUR (€) € in Thousands	Jun. 30, 2022	Dec. 31, 2021
Subclassifications of assets, liabilities and equities [abstract]
Suppliers (excluding payables related to capital expenditures)	€ 12,924	€ 14,729
Tax and employee-related payables	5,478	7,463
Other payables	13	6,380
Trade payables and others (excluding payables related to capital expenditures)	18,415	28,573
Payables related to capital expenditures	252	0
Payables and others	€ 18,667	€ 28,573

Financial liabilities - Disclos

Financial liabilities - Disclosure of financial liabilities per maturity (Details) € in Thousands		6 Months Ended
	Jan. 05, 2022 EUR (€) loan_agreement	Jun. 30, 2022 EUR (€)	Jun. 30, 2021 EUR (€)
Disclosure of financial liabilities [Line Items]
Financial liabilities at beginning of period		€ 44,252	€ 19,087
Proceeds from borrowing		0	0
Proceeds from lease liabilities and other non cash effects		155	(1,454)
Repayments of borrowings/leases liabilities		(1,032)	(1,121)
Exchange rate variation (non cash)		5	(5)
Financial liabilities at end of period		43,374	16,502
State guaranteed loan Société Générale
Disclosure of financial liabilities [Line Items]
Financial liabilities at beginning of period		20,000
Proceeds from borrowing		0
Proceeds from lease liabilities and other non cash effects		50
Repayments of borrowings/leases liabilities		0
Exchange rate variation (non cash)		0
Financial liabilities at end of period		20,050
Notional amount	€ 20,000
State guaranteed loan BNP Paribas
Disclosure of financial liabilities [Line Items]
Financial liabilities at beginning of period		8,700
Proceeds from borrowing		0
Proceeds from lease liabilities and other non cash effects		22
Repayments of borrowings/leases liabilities		0
Exchange rate variation (non cash)		0
Financial liabilities at end of period		8,722
Notional amount	8,700
BPI PTZI IPH41
Disclosure of financial liabilities [Line Items]
Financial liabilities at beginning of period			150
Proceeds from borrowing			0
Proceeds from lease liabilities and other non cash effects			0
Repayments of borrowings/leases liabilities			(150)
Exchange rate variation (non cash)			0
Financial liabilities at end of period			0
Lease liabilities – Real estate property
Disclosure of financial liabilities [Line Items]
Financial liabilities at beginning of period			1,454
Proceeds from borrowing			0
Proceeds from lease liabilities and other non cash effects			(1,454)
Repayments of borrowings/leases liabilities			0
Exchange rate variation (non cash)			0
Financial liabilities at end of period			0
Lease liabilities – Building "Le Virage"
Disclosure of financial liabilities [Line Items]
Financial liabilities at beginning of period		1,875	2,387
Proceeds from borrowing		0	0
Proceeds from lease liabilities and other non cash effects		0	0
Repayments of borrowings/leases liabilities		(260)	(255)
Exchange rate variation (non cash)		0	0
Financial liabilities at end of period		1,614	2,131
Lease liabilities – Premises Innate Inc.
Disclosure of financial liabilities [Line Items]
Financial liabilities at beginning of period		391	447
Proceeds from borrowing		0	0
Proceeds from lease liabilities and other non cash effects		45	0
Repayments of borrowings/leases liabilities		(44)	(18)
Exchange rate variation (non cash)		5	(5)
Financial liabilities at end of period		396	423
Lease liabilities – Laboratory equipment
Disclosure of financial liabilities [Line Items]
Financial liabilities at beginning of period		464	639
Proceeds from borrowing		0	0
Proceeds from lease liabilities and other non cash effects		0	0
Repayments of borrowings/leases liabilities		(87)	(87)
Exchange rate variation (non cash)		0	0
Financial liabilities at end of period		376	551
Lease liabilities – Vehicles
Disclosure of financial liabilities [Line Items]
Financial liabilities at beginning of period		53	21
Proceeds from borrowing		0	0
Proceeds from lease liabilities and other non cash effects		38	0
Repayments of borrowings/leases liabilities		(19)	(6)
Exchange rate variation (non cash)		0	0
Financial liabilities at end of period		71	14
Lease liabilities - Printers
Disclosure of financial liabilities [Line Items]
Financial liabilities at beginning of period		35	41
Proceeds from borrowing		0	0
Proceeds from lease liabilities and other non cash effects		0	0
Repayments of borrowings/leases liabilities		(4)	(2)
Exchange rate variation (non cash)		0	0
Financial liabilities at end of period		31	39
Borrowing – Equipment
Disclosure of financial liabilities [Line Items]
Financial liabilities at beginning of period		209	262
Proceeds from borrowing		0	0
Proceeds from lease liabilities and other non cash effects		0	0
Repayments of borrowings/leases liabilities		(27)	(25)
Exchange rate variation (non cash)		0	0
Financial liabilities at end of period		181	236
Borrowing – Building
Disclosure of financial liabilities [Line Items]
Financial liabilities at beginning of period		12,525	13,687
Proceeds from borrowing		0	0
Proceeds from lease liabilities and other non cash effects		0	0
Repayments of borrowings/leases liabilities		(591)	(579)
Exchange rate variation (non cash)		0	0
Financial liabilities at end of period		€ 11,933	€ 13,107
State guaranteed loan, Societe Generale and BNP Paribas
Disclosure of financial liabilities [Line Items]
Notional amount	€ 28,700
Borrowing, number of loan agreement | loan_agreement	2
Borrowing, maturity	1 year
Borrowing, maturity, extension period option	5 years
Borrowing, percentage of state-guaranteed loan	90%
Borrowings, interest rate	0.50%

Financial liabilities - Additio

Financial liabilities - Additional Information (Details) - EUR (€) € in Thousands			6 Months Ended
	Aug. 30, 2019	Jul. 03, 2017	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Disclosure of financial liabilities [Line Items]
Financial liabilities			€ 43,374	€ 16,502	€ 44,252	€ 19,087
Proceeds from borrowing			0	€ 0
Loan agreement with Société Générale
Disclosure of financial liabilities [Line Items]
Loan agreement, maximum borrowing capacity		€ 15,200
Financial liabilities			€ 11,933				€ 1,300	€ 1,300
Loan agreement, collateral		15,200
Proceeds from borrowing	€ 13,900
Borrowings, maturity period	12 years
Security interest on pledge of financial instruments will be released in 2024		4,200
Security interest on pledge of financial instruments will be released in 2027		5,000
Security interest on pledge of financial instruments will be released in 2031		€ 6,000
Loan agreement with Société Générale | Fixed interest rate
Disclosure of financial liabilities [Line Items]
Borrowings, interest rate			2.01%

Financial liabilities - Discl_2

Financial liabilities - Disclosure of maturity analysis for non-derivative financial liabilities (Details) € in Thousands	Jun. 30, 2022 EUR (€)
Statement Line Items [Line Items]
Undiscounted cash flows	€ 43,374
Within 1 year
Statement Line Items [Line Items]
Undiscounted cash flows	30,859
From 2nd to 5th year included
Statement Line Items [Line Items]
Undiscounted cash flows	6,817
Over 5 years
Statement Line Items [Line Items]
Undiscounted cash flows	5,697
State guaranteed loan Société Générale
Statement Line Items [Line Items]
Undiscounted cash flows	20,050
State guaranteed loan Société Générale | Within 1 year
Statement Line Items [Line Items]
Undiscounted cash flows	20,050
State guaranteed loan Société Générale | From 2nd to 5th year included
Statement Line Items [Line Items]
Undiscounted cash flows	0
State guaranteed loan Société Générale | Over 5 years
Statement Line Items [Line Items]
Undiscounted cash flows	0
State guaranteed loan BNP Paribas
Statement Line Items [Line Items]
Undiscounted cash flows	8,722
State guaranteed loan BNP Paribas | Within 1 year
Statement Line Items [Line Items]
Undiscounted cash flows	8,722
State guaranteed loan BNP Paribas | From 2nd to 5th year included
Statement Line Items [Line Items]
Undiscounted cash flows	0
State guaranteed loan BNP Paribas | Over 5 years
Statement Line Items [Line Items]
Undiscounted cash flows	0
Lease liabilities – Building "Le Virage"
Statement Line Items [Line Items]
Undiscounted cash flows	1,614
Lease liabilities – Building "Le Virage" | Within 1 year
Statement Line Items [Line Items]
Undiscounted cash flows	527
Lease liabilities – Building "Le Virage" | From 2nd to 5th year included
Statement Line Items [Line Items]
Undiscounted cash flows	1,088
Lease liabilities – Building "Le Virage" | Over 5 years
Statement Line Items [Line Items]
Undiscounted cash flows	0
Lease liabilities – Premises Innate Inc.
Statement Line Items [Line Items]
Undiscounted cash flows	396
Lease liabilities – Premises Innate Inc. | Within 1 year
Statement Line Items [Line Items]
Undiscounted cash flows	91
Lease liabilities – Premises Innate Inc. | From 2nd to 5th year included
Statement Line Items [Line Items]
Undiscounted cash flows	299
Lease liabilities – Premises Innate Inc. | Over 5 years
Statement Line Items [Line Items]
Undiscounted cash flows	0
Lease liabilities – Laboratory equipment
Statement Line Items [Line Items]
Undiscounted cash flows	376
Lease liabilities – Laboratory equipment | Within 1 year
Statement Line Items [Line Items]
Undiscounted cash flows	178
Lease liabilities – Laboratory equipment | From 2nd to 5th year included
Statement Line Items [Line Items]
Undiscounted cash flows	199
Lease liabilities – Laboratory equipment | Over 5 years
Statement Line Items [Line Items]
Undiscounted cash flows	0
Lease liabilities – Vehicles
Statement Line Items [Line Items]
Undiscounted cash flows	71
Lease liabilities – Vehicles | Within 1 year
Statement Line Items [Line Items]
Undiscounted cash flows	29
Lease liabilities – Vehicles | From 2nd to 5th year included
Statement Line Items [Line Items]
Undiscounted cash flows	44
Lease liabilities – Vehicles | Over 5 years
Statement Line Items [Line Items]
Undiscounted cash flows	0
Lease liabilities - Printers
Statement Line Items [Line Items]
Undiscounted cash flows	31
Lease liabilities - Printers | Within 1 year
Statement Line Items [Line Items]
Undiscounted cash flows	9
Lease liabilities - Printers | From 2nd to 5th year included
Statement Line Items [Line Items]
Undiscounted cash flows	22
Lease liabilities - Printers | Over 5 years
Statement Line Items [Line Items]
Undiscounted cash flows	0
Borrowing – Equipment
Statement Line Items [Line Items]
Undiscounted cash flows	181
Borrowing – Equipment | Within 1 year
Statement Line Items [Line Items]
Undiscounted cash flows	55
Borrowing – Equipment | From 2nd to 5th year included
Statement Line Items [Line Items]
Undiscounted cash flows	126
Borrowing – Equipment | Over 5 years
Statement Line Items [Line Items]
Undiscounted cash flows	0
Borrowing – Building
Statement Line Items [Line Items]
Undiscounted cash flows	11,933
Borrowing – Building | Within 1 year
Statement Line Items [Line Items]
Undiscounted cash flows	1,198
Borrowing – Building | From 2nd to 5th year included
Statement Line Items [Line Items]
Undiscounted cash flows	5,039
Borrowing – Building | Over 5 years
Statement Line Items [Line Items]
Undiscounted cash flows	€ 5,697

Employee benefit - Disclosure o

Employee benefit - Disclosure of defined benefit plans (Details) - EUR (€) € in Thousands	Jun. 30, 2022	Dec. 31, 2021
Disclosure of defined benefit plans [line items]
Defined benefit obligations	€ 2,696	€ 2,975
Allowance for retirement defined benefit
Disclosure of defined benefit plans [line items]
Defined benefit obligations	2,306	2,544
Allowance for seniority awards
Disclosure of defined benefit plans [line items]
Defined benefit obligations	€ 390	€ 432

Employee benefit - Disclosure_2

Employee benefit - Disclosure of net defined benefit liability (asset) (Details) - EUR (€) € in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2022	Dec. 31, 2021
Disclosure of defined benefit plans [line items]
Net defined benefit liability (asset) at beginning of period	€ 2,976	€ 4,177
Service cost	205	484
Interest costs	(14)	(47)
Actuarial (gain) / loss	(471)	(584)
Net defined benefit liability (asset) at end of period	€ 2,696	2,976
IAS19 Restatement related to change in calculation method - IFRIC
Disclosure of defined benefit plans [line items]
Net defined benefit liability (asset) at beginning of period		(1,054)
Opening balance after adjustment
Disclosure of defined benefit plans [line items]
Net defined benefit liability (asset) at beginning of period		€ 3,123

Employee benefit - Additional I

Employee benefit - Additional Information (Details)	Jun. 30, 2022	Dec. 31, 2021
Allowance for retirement defined benefit
Disclosure of defined benefit plans [line items]
Actuarial assumption of discount rates	320%	95%

Capital - Additional Informatio

Capital - Additional Information (Details)		6 Months Ended
	Jun. 30, 2021 EUR (€) shares	Jun. 30, 2022 EUR (€) € / shares shares	Jun. 30, 2021 EUR (€) shares	Dec. 31, 2021 EUR (€) shares	Dec. 31, 2020 EUR (€) shares
Disclosure of changes in the share capital
Total shareholders’ equity | €	€ 133,561,000	€ 116,333,000	€ 133,561,000	€ 107,440,000	€ 155,976,000
Par value per share (in EUR per share) | € / shares		€ 0.05
Exercise and subscription of equity instruments | €		€ 191,000	61,000
Number of own shares (in shares)		18,575		18,575
BSAAR 2012
Disclosure of changes in the share capital
Number of equity instruments converted in ordinary shares (in shares)		750
Number of other equity instruments exercised or vested in share-based payment arrangement (in shares)	86,700
Share issued, price per share (in EUR per share) | € / shares		€ 2.04
Company saving plan
Disclosure of changes in the share capital
Exercise and subscription of equity instruments (in shares)		185,280
Company saving plan, employer top-up
Disclosure of changes in the share capital
Exercise and subscription of equity instruments (in shares)		138,960
Company saving plan, employee contribution
Disclosure of changes in the share capital
Exercise and subscription of equity instruments (in shares)		46,320
Share issued, price per share (in EUR per share) | € / shares		€ 4.10
Share capital
Disclosure of changes in the share capital
Total shareholders’ equity | €	€ 3,952,000	€ 3,988,388	3,952,000	€ 3,978,000	3,950,000
Exercise and subscription of equity instruments | €		10,552	2,000
Share premium
Disclosure of changes in the share capital
Total shareholders’ equity | €	€ 373,043,000	377,998,000	373,043,000	€ 375,220,000	€ 372,131,000
Exercise and subscription of equity instruments | €		€ 180,891	€ 59,000
Ordinary Shares
Disclosure of changes in the share capital
Number of shares outstanding (in shares)		79,753,657
Par value per share (in EUR per share) | € / shares		€ 0.05
Ordinary Shares | Share capital
Disclosure of changes in the share capital
Total number of shares issued (in shares)	79,027,540	79,753,657	79,027,540	79,542,627	78,986,490
Exercise and subscription of equity instruments (in shares)		211,030	41,050
The 2016 free preferred shares
Disclosure of changes in the share capital
Par value per share (in EUR per share) | € / shares		€ 0.05
Total number of shares issued (in shares)		6,514
The 2017 free preferred shares
Disclosure of changes in the share capital
Par value per share (in EUR per share) | € / shares		€ 0.05
Total number of shares issued (in shares)		7,581

Capital - Disclosure of number

Capital - Disclosure of number and weighted average exercise prices of other equity instruments (Details)		6 Months Ended
	Jun. 30, 2021 shares	Jun. 30, 2022 shares € / shares
Warrant
Disclosure of terms and conditions of share-based payment arrangement [Line Items]
Number of free shares granted (in shares)	8,200,356
Number of other equity instruments forfeited in share-based payment arrangement (in shares)	1,314,857
Number of other equity instruments exercised or vested in share-based payment arrangement (in shares)	2,061,019
Number of other equity instruments outstanding in share-based payment arrangement (in shares)		4,824,480
Number of other equity instruments exercisable in share-based payment arrangement (in shares)		5,576,052
BSAAR 2011
Disclosure of terms and conditions of share-based payment arrangement [Line Items]
Number of free shares granted (in shares)	650,000
Number of other equity instruments forfeited in share-based payment arrangement (in shares)	25,000
Number of other equity instruments exercised or vested in share-based payment arrangement (in shares)	625,000
Number of other equity instruments outstanding in share-based payment arrangement (in shares)		0
Number of other equity instruments exercisable in share-based payment arrangement (in shares)		0
Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | € / shares		€ 2.04
BSAAR 2012
Disclosure of terms and conditions of share-based payment arrangement [Line Items]
Number of free shares granted (in shares)	146,050
Number of other equity instruments forfeited in share-based payment arrangement (in shares)	0
Number of other equity instruments exercised or vested in share-based payment arrangement (in shares)	86,700
Number of other equity instruments outstanding in share-based payment arrangement (in shares)		59,350
Number of other equity instruments exercisable in share-based payment arrangement (in shares)		59,350
Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | € / shares		€ 2.04
BSAAR 2015
Disclosure of terms and conditions of share-based payment arrangement [Line Items]
Number of free shares granted (in shares)	1,050,382
Number of other equity instruments forfeited in share-based payment arrangement (in shares)	2,720
Number of other equity instruments exercised or vested in share-based payment arrangement (in shares)	1,940
Number of other equity instruments outstanding in share-based payment arrangement (in shares)		1,045,722
Number of other equity instruments exercisable in share-based payment arrangement (in shares)		1,045,722
Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | € / shares		€ 7.20
AGAP Management 2016-1
Disclosure of terms and conditions of share-based payment arrangement [Line Items]
Number of free shares granted (in shares)	2,000
Number of other equity instruments forfeited in share-based payment arrangement (in shares)	550
Number of other equity instruments exercised or vested in share-based payment arrangement (in shares)	250
Number of other equity instruments outstanding in share-based payment arrangement (in shares)		86,700
Number of other equity instruments exercisable in share-based payment arrangement (in shares)		59,350
Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | € / shares		€ 59,350
AGAP Employees 2016-1
Disclosure of terms and conditions of share-based payment arrangement [Line Items]
Number of free shares granted (in shares)	2,486
Number of other equity instruments forfeited in share-based payment arrangement (in shares)	251
Number of other equity instruments exercised or vested in share-based payment arrangement (in shares)	167
Number of other equity instruments outstanding in share-based payment arrangement (in shares)		2,068
Number of other equity instruments exercisable in share-based payment arrangement (in shares)		268,840
Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | € / shares		€ 0
AGA Management 2016-1
Disclosure of terms and conditions of share-based payment arrangement [Line Items]
Number of free shares granted (in shares)	50,000
Number of other equity instruments forfeited in share-based payment arrangement (in shares)	0
Number of other equity instruments exercised or vested in share-based payment arrangement (in shares)	50,000
Number of other equity instruments outstanding in share-based payment arrangement (in shares)		0
Number of other equity instruments exercisable in share-based payment arrangement (in shares)		0
Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | € / shares		€ 0
AGAP Management 2016-2
Disclosure of terms and conditions of share-based payment arrangement [Line Items]
Number of free shares granted (in shares)	3,000
Number of other equity instruments forfeited in share-based payment arrangement (in shares)	0
Number of other equity instruments exercised or vested in share-based payment arrangement (in shares)	0
Number of other equity instruments outstanding in share-based payment arrangement (in shares)		3,000
Number of other equity instruments exercisable in share-based payment arrangement (in shares)		333,000
Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | € / shares		€ 0
AGA Management 2016-2
Disclosure of terms and conditions of share-based payment arrangement [Line Items]
Number of free shares granted (in shares)	250,000
Number of other equity instruments forfeited in share-based payment arrangement (in shares)	0
Number of other equity instruments exercised or vested in share-based payment arrangement (in shares)	250,000
Number of other equity instruments outstanding in share-based payment arrangement (in shares)		0
Number of other equity instruments exercisable in share-based payment arrangement (in shares)		0
Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | € / shares		€ 0
AGAP Employees 2017-1
Disclosure of terms and conditions of share-based payment arrangement [Line Items]
Number of free shares granted (in shares)	5,725
Number of other equity instruments forfeited in share-based payment arrangement (in shares)	5,725
Number of other equity instruments exercised or vested in share-based payment arrangement (in shares)	0
Number of other equity instruments outstanding in share-based payment arrangement (in shares)		0
Number of other equity instruments exercisable in share-based payment arrangement (in shares)		0
Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | € / shares		€ 0
AGAP Management 2017-1
Disclosure of terms and conditions of share-based payment arrangement [Line Items]
Number of free shares granted (in shares)	2,400
Number of other equity instruments forfeited in share-based payment arrangement (in shares)	2,400
Number of other equity instruments exercised or vested in share-based payment arrangement (in shares)	0
Number of other equity instruments outstanding in share-based payment arrangement (in shares)		0
Number of other equity instruments exercisable in share-based payment arrangement (in shares)		0
Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | € / shares		€ 0
AGA Employees 2017
Disclosure of terms and conditions of share-based payment arrangement [Line Items]
Number of free shares granted (in shares)	114,500
Number of other equity instruments forfeited in share-based payment arrangement (in shares)	4,000
Number of other equity instruments exercised or vested in share-based payment arrangement (in shares)	110,500
Number of other equity instruments outstanding in share-based payment arrangement (in shares)		0
Number of other equity instruments exercisable in share-based payment arrangement (in shares)		0
Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | € / shares		€ 0
AGA Bonus 2018-1
Disclosure of terms and conditions of share-based payment arrangement [Line Items]
Number of free shares granted (in shares)	67,028
Number of other equity instruments forfeited in share-based payment arrangement (in shares)	469
Number of other equity instruments exercised or vested in share-based payment arrangement (in shares)	66,559
Number of other equity instruments outstanding in share-based payment arrangement (in shares)		0
Number of other equity instruments exercisable in share-based payment arrangement (in shares)		0
Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | € / shares		€ 0
AGAP Perf Employees 2018-1
Disclosure of terms and conditions of share-based payment arrangement [Line Items]
Number of free shares granted (in shares)	327,500
Number of other equity instruments forfeited in share-based payment arrangement (in shares)	224,375
Number of other equity instruments exercised or vested in share-based payment arrangement (in shares)	103,125
Number of other equity instruments outstanding in share-based payment arrangement (in shares)		0
Number of other equity instruments exercisable in share-based payment arrangement (in shares)		0
Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | € / shares		€ 0
AGAP Perf Management 2018-1
Disclosure of terms and conditions of share-based payment arrangement [Line Items]
Number of free shares granted (in shares)	260,000
Number of other equity instruments forfeited in share-based payment arrangement (in shares)	150,000
Number of other equity instruments exercised or vested in share-based payment arrangement (in shares)	110,000
Number of other equity instruments outstanding in share-based payment arrangement (in shares)		0
Number of other equity instruments exercisable in share-based payment arrangement (in shares)		0
Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | € / shares		€ 0
AGA Employees 2018
Disclosure of terms and conditions of share-based payment arrangement [Line Items]
Number of free shares granted (in shares)	90,650
Number of other equity instruments forfeited in share-based payment arrangement (in shares)	5,000
Number of other equity instruments exercised or vested in share-based payment arrangement (in shares)	85,650
Number of other equity instruments outstanding in share-based payment arrangement (in shares)		0
Number of other equity instruments exercisable in share-based payment arrangement (in shares)		0
Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | € / shares		€ 0
AGA New Members 2017-1
Disclosure of terms and conditions of share-based payment arrangement [Line Items]
Number of free shares granted (in shares)	25,000
Number of other equity instruments forfeited in share-based payment arrangement (in shares)	0
Number of other equity instruments exercised or vested in share-based payment arrangement (in shares)	25,000	25,000
Number of other equity instruments outstanding in share-based payment arrangement (in shares)		0
Number of other equity instruments exercisable in share-based payment arrangement (in shares)		0
Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | € / shares		€ 0
AGA Bonus 2019-1
Disclosure of terms and conditions of share-based payment arrangement [Line Items]
Number of free shares granted (in shares)	57,376
Number of other equity instruments forfeited in share-based payment arrangement (in shares)	0
Number of other equity instruments exercised or vested in share-based payment arrangement (in shares)	57,376
Number of other equity instruments outstanding in share-based payment arrangement (in shares)		0
Number of other equity instruments exercisable in share-based payment arrangement (in shares)		0
Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | € / shares		€ 0
AGA Bonus 2020-1
Disclosure of terms and conditions of share-based payment arrangement [Line Items]
Number of free shares granted (in shares)	79,861
Number of other equity instruments forfeited in share-based payment arrangement (in shares)	17,885
Number of other equity instruments exercised or vested in share-based payment arrangement (in shares)	48,362
Number of other equity instruments outstanding in share-based payment arrangement (in shares)		13,614
Number of other equity instruments exercisable in share-based payment arrangement (in shares)		13,614
Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | € / shares		€ 0
AGAP Employees 2020-1
Disclosure of terms and conditions of share-based payment arrangement [Line Items]
Number of free shares granted (in shares)	766,650
Number of other equity instruments forfeited in share-based payment arrangement (in shares)	269,282
Number of other equity instruments exercised or vested in share-based payment arrangement (in shares)	0
Number of other equity instruments outstanding in share-based payment arrangement (in shares)		497,368
Number of other equity instruments exercisable in share-based payment arrangement (in shares)		497,368
Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | € / shares		€ 0
AGAP Management 2020-1
Disclosure of terms and conditions of share-based payment arrangement [Line Items]
Number of free shares granted (in shares)	710,000
Number of other equity instruments forfeited in share-based payment arrangement (in shares)	60,000
Number of other equity instruments exercised or vested in share-based payment arrangement (in shares)	0
Number of other equity instruments outstanding in share-based payment arrangement (in shares)		650,000
Number of other equity instruments exercisable in share-based payment arrangement (in shares)		650,000
Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | € / shares		€ 0
AGA Bonus 2021-1
Disclosure of terms and conditions of share-based payment arrangement [Line Items]
Number of free shares granted (in shares)	125,748
Number of other equity instruments forfeited in share-based payment arrangement (in shares)	0
Number of other equity instruments exercised or vested in share-based payment arrangement (in shares)	0
Number of other equity instruments outstanding in share-based payment arrangement (in shares)		125,748
Number of other equity instruments exercisable in share-based payment arrangement (in shares)		125,748
Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | € / shares		€ 0
AGAP Employees 2021-1
Disclosure of terms and conditions of share-based payment arrangement [Line Items]
Number of free shares granted (in shares)	1,066,600
Number of other equity instruments forfeited in share-based payment arrangement (in shares)	67,800
Number of other equity instruments exercised or vested in share-based payment arrangement (in shares)	0
Number of other equity instruments outstanding in share-based payment arrangement (in shares)		998,800
Number of other equity instruments exercisable in share-based payment arrangement (in shares)		998,800
Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | € / shares		€ 0
AGAP Management 2021-1
Disclosure of terms and conditions of share-based payment arrangement [Line Items]
Number of free shares granted (in shares)	610,000
Number of other equity instruments forfeited in share-based payment arrangement (in shares)	90,000
Number of other equity instruments exercised or vested in share-based payment arrangement (in shares)	0
Number of other equity instruments outstanding in share-based payment arrangement (in shares)		520,000
Number of other equity instruments exercisable in share-based payment arrangement (in shares)		520,000
Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | € / shares		€ 0
Stock Options 2020-1
Disclosure of terms and conditions of share-based payment arrangement [Line Items]
Number of free shares granted (in shares)	102,000
Number of other equity instruments forfeited in share-based payment arrangement (in shares)	102,000
Number of other equity instruments exercised or vested in share-based payment arrangement (in shares)	0
Number of other equity instruments outstanding in share-based payment arrangement (in shares)		0
Number of other equity instruments exercisable in share-based payment arrangement (in shares)		0
Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | € / shares		€ 0
AGAP 2019 Employees 2019
Disclosure of terms and conditions of share-based payment arrangement [Line Items]
Number of free shares granted (in shares)	546,700
Number of other equity instruments forfeited in share-based payment arrangement (in shares)	202,400
Number of other equity instruments exercised or vested in share-based payment arrangement (in shares)	0
Number of other equity instruments outstanding in share-based payment arrangement (in shares)		344,300
Number of other equity instruments exercisable in share-based payment arrangement (in shares)		344,300
Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | € / shares		€ 0
AGAP 2019 Management 2019
Disclosure of terms and conditions of share-based payment arrangement [Line Items]
Number of free shares granted (in shares)	355,000
Number of other equity instruments forfeited in share-based payment arrangement (in shares)	60,000
Number of other equity instruments exercised or vested in share-based payment arrangement (in shares)	0
Number of other equity instruments outstanding in share-based payment arrangement (in shares)		295,000
Number of other equity instruments exercisable in share-based payment arrangement (in shares)		295,000
Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | € / shares		€ 0
BSA 2011-2
Disclosure of terms and conditions of share-based payment arrangement [Line Items]
Number of free shares granted (in shares)	225,000
Number of other equity instruments forfeited in share-based payment arrangement (in shares)	25,000
Number of other equity instruments exercised or vested in share-based payment arrangement (in shares)	200,000
Number of other equity instruments outstanding in share-based payment arrangement (in shares)		0
Number of other equity instruments exercisable in share-based payment arrangement (in shares)		0
Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | € / shares		€ 1.77
BSA 2013
Disclosure of terms and conditions of share-based payment arrangement [Line Items]
Number of free shares granted (in shares)	237,500
Number of other equity instruments forfeited in share-based payment arrangement (in shares)	0
Number of other equity instruments exercised or vested in share-based payment arrangement (in shares)	191,140
Number of other equity instruments outstanding in share-based payment arrangement (in shares)		46,360
Number of other equity instruments exercisable in share-based payment arrangement (in shares)		46,360
Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | € / shares		€ 2.36
BSA 2014
Disclosure of terms and conditions of share-based payment arrangement [Line Items]
Number of free shares granted (in shares)	150,000
Number of other equity instruments forfeited in share-based payment arrangement (in shares)	0
Number of other equity instruments exercised or vested in share-based payment arrangement (in shares)	75,000
Number of other equity instruments outstanding in share-based payment arrangement (in shares)		75,000
Number of other equity instruments exercisable in share-based payment arrangement (in shares)		75,000
Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | € / shares		€ 8.65
BSA 2015-1
Disclosure of terms and conditions of share-based payment arrangement [Line Items]
Number of free shares granted (in shares)	70,000
Number of other equity instruments forfeited in share-based payment arrangement (in shares)	0
Number of other equity instruments exercised or vested in share-based payment arrangement (in shares)	0
Number of other equity instruments outstanding in share-based payment arrangement (in shares)		70,000
Number of other equity instruments exercisable in share-based payment arrangement (in shares)		70,000
Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | € / shares		€ 9.59
BSA 2015-2
Disclosure of terms and conditions of share-based payment arrangement [Line Items]
Number of free shares granted (in shares)	14,200
Number of other equity instruments forfeited in share-based payment arrangement (in shares)	0
Number of other equity instruments exercised or vested in share-based payment arrangement (in shares)	0
Number of other equity instruments outstanding in share-based payment arrangement (in shares)		14,200
Number of other equity instruments exercisable in share-based payment arrangement (in shares)		14,200
Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | € / shares		€ 14.05
BSA 2017
Disclosure of terms and conditions of share-based payment arrangement [Line Items]
Number of free shares granted (in shares)	37,000
Number of other equity instruments forfeited in share-based payment arrangement (in shares)	0
Number of other equity instruments exercised or vested in share-based payment arrangement (in shares)	0
Number of other equity instruments outstanding in share-based payment arrangement (in shares)		37,000
Number of other equity instruments exercisable in share-based payment arrangement (in shares)		37,000
Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | € / shares		€ 11

Financial instruments recogni_3

Financial instruments recognized in the statement of financial position and related effect on the income statement (Details) - EUR (€) € in Thousands	Jun. 30, 2022	Dec. 31, 2021
Disclosure of detailed information about financial instruments [line items]
Financial assets	€ 219,687	€ 207,955
Financial assets, fair value	219,687	207,955
Financial liabilities	62,041	72,824
Financial liabilities, fair value	62,041	72,824
Financial liabilities at fair value through profit or loss, category
Disclosure of detailed information about financial instruments [line items]
Financial liabilities	0	0
Financial liabilities at amortised cost, category
Disclosure of detailed information about financial instruments [line items]
Financial liabilities	62,041	72,824
Financial liabilities—non-current portion
Disclosure of detailed information about financial instruments [line items]
Financial liabilities	12,523	13,503
Financial liabilities, fair value	12,523	13,503
Financial liabilities—non-current portion | Financial liabilities at fair value through profit or loss, category
Disclosure of detailed information about financial instruments [line items]
Financial liabilities	0	0
Financial liabilities—non-current portion | Financial liabilities at amortised cost, category
Disclosure of detailed information about financial instruments [line items]
Financial liabilities	12,523	13,503
Financial liabilities—current portion
Disclosure of detailed information about financial instruments [line items]
Financial liabilities	30,851	30,748
Financial liabilities, fair value	30,851	30,748
Financial liabilities—current portion | Financial liabilities at fair value through profit or loss, category
Disclosure of detailed information about financial instruments [line items]
Financial liabilities	0	0
Financial liabilities—current portion | Financial liabilities at amortised cost, category
Disclosure of detailed information about financial instruments [line items]
Financial liabilities	30,851	30,748
Trade payables and others
Disclosure of detailed information about financial instruments [line items]
Financial liabilities	18,667	28,573
Financial liabilities, fair value	18,667	28,573
Trade payables and others | Financial liabilities at fair value through profit or loss, category
Disclosure of detailed information about financial instruments [line items]
Financial liabilities	0	0
Trade payables and others | Financial liabilities at amortised cost, category
Disclosure of detailed information about financial instruments [line items]
Financial liabilities	18,667	28,573
Financial assets at fair value through profit or loss, category
Disclosure of detailed information about financial instruments [line items]
Financial assets	158,156	159,714
Financial assets at amortised cost, category
Disclosure of detailed information about financial instruments [line items]
Financial assets	61,531	48,241
Non-current financial assets
Disclosure of detailed information about financial instruments [line items]
Financial assets	34,806	39,878
Financial assets, fair value	34,806	39,878
Non-current financial assets | Financial assets at fair value through profit or loss, category
Disclosure of detailed information about financial instruments [line items]
Financial assets	34,806	39,878
Non-current financial assets | Financial assets at amortised cost, category
Disclosure of detailed information about financial instruments [line items]
Financial assets	0	0
Trade receivables and others
Disclosure of detailed information about financial instruments [line items]
Financial assets	61,531	48,241
Financial assets, fair value	61,531	48,241
Trade receivables and others | Financial assets at fair value through profit or loss, category
Disclosure of detailed information about financial instruments [line items]
Financial assets	0	0
Trade receivables and others | Financial assets at amortised cost, category
Disclosure of detailed information about financial instruments [line items]
Financial assets	61,531	48,241
Short-term investments
Disclosure of detailed information about financial instruments [line items]
Financial assets	20,401	16,080
Financial assets, fair value	20,401	16,080
Short-term investments | Financial assets at fair value through profit or loss, category
Disclosure of detailed information about financial instruments [line items]
Financial assets	20,401	16,080
Short-term investments | Financial assets at amortised cost, category
Disclosure of detailed information about financial instruments [line items]
Financial assets	0	0
Cash and cash equivalents
Disclosure of detailed information about financial instruments [line items]
Financial assets	102,949	103,756
Financial assets, fair value	102,949	103,756
Cash and cash equivalents | Financial assets at fair value through profit or loss, category
Disclosure of detailed information about financial instruments [line items]
Financial assets	102,949	103,756
Cash and cash equivalents | Financial assets at amortised cost, category
Disclosure of detailed information about financial instruments [line items]
Financial assets	€ 0	€ 0

Revenue, government financing_3

Revenue, government financing for research expenditures and sales - Disclosure of revenue from collaboration and licensing agreements (Details) - EUR (€) € in Thousands	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Disclosure of disaggregation of revenue from contracts with customers [line items]
Revenue from collaboration and licensing agreements	€ 41,271	€ 8,304	[1]
Proceeds from collaboration and licensing agreements
Disclosure of disaggregation of revenue from contracts with customers [line items]
Revenue from collaboration and licensing agreements	41,919	7,095
Monalizumab agreement (AstraZeneca)
Disclosure of disaggregation of revenue from contracts with customers [line items]
Revenue from collaboration and licensing agreements	16,440	6,095
IPH5201 agreement (AstraZeneca)
Disclosure of disaggregation of revenue from contracts with customers [line items]
Revenue from collaboration and licensing agreements	4,826	0
Preclinical molecules agreement (AstraZeneca)
Disclosure of disaggregation of revenue from contracts with customers [line items]
Revenue from collaboration and licensing agreements	17,400	0
Sanofi agreement
Disclosure of disaggregation of revenue from contracts with customers [line items]
Revenue from collaboration and licensing agreements	3,000	1,000
Other agreements
Disclosure of disaggregation of revenue from contracts with customers [line items]
Revenue from collaboration and licensing agreements	252	0
Invoicing of R&D costs (IPH5201 and advoralimab agreements)
Disclosure of disaggregation of revenue from contracts with customers [line items]
Revenue from collaboration and licensing agreements	(21)	1,209
Exchange gains or losses on collaboration agreement
Disclosure of disaggregation of revenue from contracts with customers [line items]
Revenue from collaboration and licensing agreements	€ (627)	€ 0
[1]Comparative relating to the six months ended June 30, 2021 have been restated to reflect the impact of the classification of Lumoxiti's activities as discontinued operations in 2021. See note 17 of the interim condensed consolidated financial statements as of June 30, 2022.

Revenue, government financing_4

Revenue, government financing for research expenditures and sales - Disclosure of change in deferred revenue and collaboration liabilities (Details) € in Thousands, $ in Thousands			6 Months Ended
	Jun. 17, 2022 USD ($)	Jun. 17, 2022 EUR (€)	Jun. 30, 2022 EUR (€)	Jun. 30, 2021 EUR (€)
2015 monalizumab agreement, with AstraZeneca
Collaboration Liabilities, Roll Forward [Abstract]
Milestone payment received	$ 50,000	€ 47,687
Deferred revenue
Deferred Revenue, Roll Forward [Abstract]
Contract liabilities at beginning of period			€ 37,912	€ 43,973
Revenue for the six months period/Deduction			(34,075)	(6,095)
Contract liabilities at end of period			17,427	38,066
Collaboration Liabilities, Roll Forward [Abstract]
Contract liabilities at beginning of period			37,912	43,973
Contract liabilities at end of period			17,427	38,066
Deferred revenue | 2015 monalizumab agreement, with AstraZeneca
Deferred Revenue, Roll Forward [Abstract]
Contract liabilities at beginning of period			20,159	26,572
Increase in deferred revenue/Augmentation			47,687
Revenue for the six months period/Deduction			(16,440)	(6,095)
Transfer from / (to) collaboration liabilities			(34,094)	188
Contract liabilities at end of period			17,312	20,665
Collaboration Liabilities, Roll Forward [Abstract]
Contract liabilities at beginning of period			20,159	26,572
Contract liabilities at end of period			17,312	20,665
Deferred revenue | IPH43, IPH25, IPH26 and IPH62, with AstraZeneca
Deferred Revenue, Roll Forward [Abstract]
Contract liabilities at beginning of period				17,400
Increase in deferred revenue/Augmentation				0
Revenue for the six months period/Deduction				(17,400)
Contract liabilities at end of period				0
Collaboration Liabilities, Roll Forward [Abstract]
Contract liabilities at beginning of period				17,400
Contract liabilities at end of period				0
Collaboration liabilities | 2015 monalizumab agreement, with AstraZeneca
Deferred Revenue, Roll Forward [Abstract]
Contract liabilities at beginning of period			40,415	46,686
Contract liabilities at end of period			73,121	45,934
Collaboration Liabilities, Roll Forward [Abstract]
Contract liabilities at beginning of period			40,415	46,686
Additions	$ 36,000	€ 34,335	38,568	1,501
Deductions			(5,862)	(2,253)
Contract liabilities at end of period			73,121	€ 45,934
Increase through net exchange differences			€ 3,700

Revenue, government financing_5

Revenue, government financing for research expenditures and sales - Additional Information (Details) € in Thousands, $ in Millions		6 Months Ended
	Jun. 01, 2022 USD ($)	Jun. 30, 2022 EUR (€) program	Jun. 30, 2022 USD ($) program	Jun. 30, 2021 EUR (€)		Jun. 02, 2022 program
Disclosure of disaggregation of revenue from contracts with customers [line items]
Revenue from collaboration and licensing agreements		€ 41,271		€ 8,304	[1]
Income from government grants		49		1,435
BPI Refundable advance - FORCE
Disclosure of disaggregation of revenue from contracts with customers [line items]
Income from government grants				1,360
IPH5201 agreement, with AstraZeneca
Disclosure of disaggregation of revenue from contracts with customers [line items]
Revenue from collaboration and licensing agreements		4,826		0
Collaboration milestone payments receivable | $	$ 5
IPH43, IPH25, IPH26 and IPH62, with AstraZeneca
Disclosure of disaggregation of revenue from contracts with customers [line items]
Revenue from collaboration and licensing agreements		€ 17,400	$ 20
Number of underlying programs terminated | program		4	4			4
IPH6101 agreement, with Sanofi
Disclosure of disaggregation of revenue from contracts with customers [line items]
Revenue from collaboration and licensing agreements		€ 3,000		€ 1,000
[1]Comparative relating to the six months ended June 30, 2021 have been restated to reflect the impact of the classification of Lumoxiti's activities as discontinued operations in 2021. See note 17 of the interim condensed consolidated financial statements as of June 30, 2022.

Revenue, government financing_6

Revenue, government financing for research expenditures and sales - Disclosure of variance of deferred revenue (Details) - Deferred revenue - EUR (€) € in Thousands	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Disclosure of disaggregation of revenue from contracts with customers [line items]
Contract liabilities at beginning of period	€ 37,912	€ 43,973
Recognition in P&L	(34,075)	(6,095)
Proceeds	47,687	0
Transfer from / (to) collaboration liabilities	(34,094)	188
Contract liabilities at end of period	17,427	38,066
Monalizumab
Disclosure of disaggregation of revenue from contracts with customers [line items]
Contract liabilities at beginning of period	20,159	26,572
Recognition in P&L	(16,440)	(6,095)
Proceeds	47,687	0
Transfer from / (to) collaboration liabilities	(34,094)	188
Contract liabilities at end of period	17,310	20,665
IPH5201
Disclosure of disaggregation of revenue from contracts with customers [line items]
Contract liabilities at beginning of period	0	0
Recognition in P&L	0	0
Proceeds	0	0
Transfer from / (to) collaboration liabilities	0	0
Contract liabilities at end of period	0	0
Preclinical molecules
Disclosure of disaggregation of revenue from contracts with customers [line items]
Contract liabilities at beginning of period	17,400	17,400
Recognition in P&L	(17,400)	0
Proceeds	0	0
Transfer from / (to) collaboration liabilities	0	0
Contract liabilities at end of period	0	€ 17,400
Others
Disclosure of disaggregation of revenue from contracts with customers [line items]
Contract liabilities at beginning of period	353
Recognition in P&L	(235)
Proceeds	0
Transfer from / (to) collaboration liabilities	0
Contract liabilities at end of period	€ 117

Revenue, government financing_7

Revenue, government financing for research expenditures and sales - Disclosure of government financing for research expenditures (Details) - EUR (€) € in Thousands	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Disclosure of disaggregation of revenue from contracts with customers [abstract]
Research tax credit	€ 4,270	€ 4,933
Grant	49	1,435
Government financing for research expenditures	€ 4,319	€ 6,368	[1]
[1]Comparative relating to the six months ended June 30, 2021 have been restated to reflect the impact of the classification of Lumoxiti's activities as discontinued operations in 2021. See note 17 of the interim condensed consolidated financial statements as of June 30, 2022.

Operating expenses - Disclosure

Operating expenses - Disclosure of expenses by nature (Details) - EUR (€) € in Thousands	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Statement Line Items [Line Items]
Subcontracting costs	€ (10,727)	€ (10,193)
Cost of supplies and consumable materials	(1,948)	(2,180)
Personnel expenses other than share-based compensation	(11,895)	(11,400)
Share-based compensation	(2,596)	(852)
Personnel expenses	(14,491)	(12,252)
Non-scientific advisory and consulting	(2,994)	(2,676)
Leasing and maintenance	(1,058)	(1,148)
Travel expenses and meeting attendance	(354)	(58)
Marketing, communication and public relations	(459)	(159)
Scientific advisory and consulting	(360)	(79)
Other purchases and external expenses	(1,132)	(1,255)
Depreciation and amortization	(2,042)	(2,161)
Intellectual property expenses	(668)	(798)
Other income and (expenses), net	(863)	(892)
Operating expenses	(37,096)	(33,851)	[1]
Operating expenses | R&D
Statement Line Items [Line Items]
Subcontracting costs	(10,727)	(10,179)
Cost of supplies and consumable materials	(1,663)	(1,513)
Personnel expenses other than share-based compensation	(7,447)	(6,827)
Share-based compensation	(1,275)	(219)
Personnel expenses	(8,722)	(7,046)
Non-scientific advisory and consulting	(752)	(175)
Leasing and maintenance	(97)	(131)
Travel expenses and meeting attendance	(245)	(22)
Marketing, communication and public relations	(84)	(44)
Scientific advisory and consulting	(360)	4
Other purchases and external expenses	(9)	0
Depreciation and amortization	(1,274)	(1,473)
Intellectual property expenses	(492)	(779)
Other income and (expenses), net	(531)	151
Operating expenses	(24,956)	(21,208)
Operating expenses | G&A
Statement Line Items [Line Items]
Subcontracting costs	0	(13)
Cost of supplies and consumable materials	(285)	(666)
Personnel expenses other than share-based compensation	(4,448)	(4,573)
Share-based compensation	(1,321)	(633)
Personnel expenses	(5,769)	(5,206)
Non-scientific advisory and consulting	(2,242)	(2,501)
Leasing and maintenance	(961)	(1,017)
Travel expenses and meeting attendance	(109)	(36)
Marketing, communication and public relations	(375)	(115)
Scientific advisory and consulting	0	(83)
Other purchases and external expenses	(1,123)	(1,255)
Depreciation and amortization	(768)	(689)
Intellectual property expenses	(176)	(20)
Other income and (expenses), net	(332)	(1,043)
Operating expenses	€ (12,140)	€ (12,643)
[1]Comparative relating to the six months ended June 30, 2021 have been restated to reflect the impact of the classification of Lumoxiti's activities as discontinued operations in 2021. See note 17 of the interim condensed consolidated financial statements as of June 30, 2022.

Operating expenses - Additional

Operating expenses - Additional Information (Details) € in Thousands	6 Months Ended
	Jun. 30, 2022 EUR (€) employee	Jun. 30, 2021 EUR (€) employee
Analysis of income and expense [abstract]
Personnel expenses other than share-based compensation | €	€ 11,895	€ 11,400
Number of employees | employee	213	212

Net financial income _ (loss)_2

Net financial income / (loss) (Details) - EUR (€) € in Thousands	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Analysis of income and expense [abstract]
Interests on financial assets	€ 198	€ 171
Change in valuation allowance on financial instruments	53	1,040
Foreign exchange gains	3,797	2,185
Other financial income	0	94
Financial income	4,048	3,490	[1]
Foreign exchange losses	(3,663)	(1,602)
Unrealized losses on financial assets	(2,309)	0
Interest on financial liabilities	(194)	(160)
Other financial expenses	0	(18)
Financial expenses	(6,166)	(1,781)	[1]
Net financial income (loss)	€ (2,118)	€ 1,709	[1]
[1]Comparative relating to the six months ended June 30, 2021 have been restated to reflect the impact of the classification of Lumoxiti's activities as discontinued operations in 2021. See note 17 of the interim condensed consolidated financial statements as of June 30, 2022.

Income tax _ (expense) (Details

Income tax / (expense) (Details) $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2022 EUR (€)	Dec. 31, 2022	Jun. 30, 2022 USD ($)	Dec. 31, 2021 EUR (€)	Dec. 31, 2021 USD ($)
Disclosure Of Income Tax [Line Items]
Current tax expense (income)	€ 0
Unused tax losses with no expiration date	€ 392,359,000			€ 392,359,000
Expiration period	20 years
Unused tax losses subject to expiration, indefinite carryforward	€ 14,967,000			14,967,000
Unused tax losses subject to expiration, 20 year carryforward	515,000			515,000
Unused tax losses subject to expiration	€ 15,482,000		$ 16,081	€ 15,482,000	$ 16,081
Forecast
Disclosure Of Income Tax [Line Items]
Applicable tax rate		0%

Discontinued Operations - Discl

Discontinued Operations - Disclosure of analysis of financial performance of discontinued operations (Details) - EUR (€) € in Thousands	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Revenue and other income
Revenue from collaboration and licensing agreements	€ 41,271	€ 8,304	[1]
Sales	0	0	[1]
Revenue and other income	45,589	14,671	[1]
Operating expenses
Research and development expenses	(24,956)	(21,208)	[1]
Operating expenses	(37,096)	(33,851)	[1]
Operating income (loss)	8,494	(19,179)	[1]
Financial income	4,048	3,490	[1]
Financial expenses	(6,166)	(1,781)	[1]
Net financial income (loss)	(2,118)	1,709	[1]
Net income (loss) before tax	6,376	(17,470)	[1]
Income tax expense	0	0
Net income (loss) from discontinued operations	(73)	(6,249)	[1]
Discontinued operations
Revenue and other income
Revenue from collaboration and licensing agreements	0	0
Sales	42	1,015
Revenue and other income	42	1,015
Operating expenses
Research and development expenses	(11)	(586)
Selling, general and administrative expenses	(104)	(6,678)
Impairment of intangible assets	0	0
Operating expenses	(115)	(7,264)
Net income (loss) from distribution agreements	0	0
Operating income (loss)	(73)	(6,249)
Financial income	0	0
Financial expenses	0	0
Net financial income (loss)	0	0
Net income (loss) before tax	€ (73)	€ (6,249)
[1]Comparative relating to the six months ended June 30, 2021 have been restated to reflect the impact of the classification of Lumoxiti's activities as discontinued operations in 2021. See note 17 of the interim condensed consolidated financial statements as of June 30, 2022.

Discontinued Operations - Dis_2

Discontinued Operations - Disclosure of analysis of cash-flows from discontinued operations (Details) - EUR (€) € in Thousands	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Discontinued Operations [Abstract]
Net cash generated from / (used in) operating activities	€ (5,539)	€ (4,398)
Net cash generated from / (used in) investing activities	0	0
Net cash generated from / (used in) financing activities	0	0
Net cash flows from discontinued operations	€ (5,539)	€ (4,398)

Commitments, contingencies an_2

Commitments, contingencies and litigation (Details) € in Thousands, $ in Millions		6 Months Ended
	Jun. 01, 2022 USD ($)	Jun. 30, 2022 EUR (€)	Dec. 31, 2021 EUR (€)
Disclosure of contingent liabilities [table]
Non-cancellable off-balance sheet purchase commitments		€ 2,666
Total provisions		1,035	€ 900
Preclinical work
Disclosure of contingent liabilities [table]
Non-cancellable off-balance sheet purchase commitments		2,485
Clinical work
Disclosure of contingent liabilities [table]
Non-cancellable off-balance sheet purchase commitments		181
IPH5201 (anti-CD39) rights acquired from Orega Biotech
Disclosure of contingent liabilities [table]
Provision for charges		€ 578
IPH5201 agreement, with AstraZeneca
Disclosure of contingent liabilities [table]
Collaboration milestone payments receivable | $	$ 5

Related party transactions - Di

Related party transactions - Disclosure of key management personnel compensation (Details) - EUR (€) € in Thousands	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Related party transactions [abstract]
Personnel and other short-term employee benefits	€ 1,205	€ 1,881
Extra pension benefits	11	0
Share-based compensation	891	538
Executive Board Members and other Executive Members compensation	€ 2,107	€ 2,419

Related party transactions - Ad

Related party transactions - Additional Information (Details) € in Thousands	Apr. 04, 2022 EUR (€)	Dec. 17, 2021	Feb. 02, 2021 EUR (€)	Jun. 30, 2022 EUR (€) licensing_agreement
Disclosure of transactions between related parties [Line Items]
Provision for attendance fees				€ 176
Amounts payable, related party transactions				€ 5,121
Novo Nordisk A/S
Disclosure of transactions between related parties [Line Items]
Number of licensing agreements | licensing_agreement				3
Amounts payable, related party transactions				€ 0
Mi-mAbs
Disclosure of transactions between related parties [Line Items]
Maximum services to be received, related party transactions	€ 1,000		€ 600
Service agreement, period			1 year
Service agreement, renewal period		1 year

Related party transactions - _2

Related party transactions - Disclosure of transactions between related parties (Details) € in Thousands	6 Months Ended
	Jun. 30, 2022 EUR (€)
Related party transactions [abstract]
Collection	€ 48,744
Receivables	5,691
Payments	(11,535)
Liabilities	(5,121)
Net collection (payments)	37,209
Net receivables (liabilities)	€ 570

Income _ (loss) per share (Deta

Income / (loss) per share (Details) - EUR (€) € / shares in Units, € in Thousands	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Income (Loss) Per Share [Abstract]
Net income (loss)	€ 6,303	€ (23,719)	[1]
Weighted average number of ordinary shares in circulation (in shares)	79,753,657	78,997,954	[1]
Basic income/(loss) per share (in EUR per share)	€ 0.08	€ (0.30)	[1]
Adjustment for share instruments (in shares)	2,132,098	0
Diluted income/(loss) per share (in EUR per share)	€ 0.08	€ (0.30)	[1]
[1]Comparative relating to the six months ended June 30, 2021 have been restated to reflect the impact of the classification of Lumoxiti's activities as discontinued operations in 2021. See note 17 of the interim condensed consolidated financial statements as of June 30, 2022.

Events after the reporting da_2

Events after the reporting date (Details) € in Millions, $ in Millions	Jan. 05, 2022 EUR (€) loan_agreement	Sep. 15, 2022	Sep. 30, 2020 USD ($)
State guaranteed loan, Societe Generale and BNP Paribas
Disclosure of non-adjusting events after reporting period [line items]
Borrowing, number of loan agreement | loan_agreement	2
Notional amount	€ 28.7
Borrowing, maturity	1 year
Borrowing, maturity, extension period option	5 years
State guaranteed loan Société Générale
Disclosure of non-adjusting events after reporting period [line items]
Notional amount	€ 20
State guaranteed loan BNP Paribas
Disclosure of non-adjusting events after reporting period [line items]
Notional amount	€ 8.7
2015 monalizumab agreement, with AstraZeneca
Disclosure of non-adjusting events after reporting period [line items]
Additional milestones payment receivable | $			$ 50
Major loan financing | State guaranteed loan Société Générale
Disclosure of non-adjusting events after reporting period [line items]
Borrowings, interest rate		1.56%
Major loan financing | State guaranteed loan BNP Paribas
Disclosure of non-adjusting events after reporting period [line items]
Borrowings, interest rate		0.95%

Uncategorized Items - _IXDS

Label	Element	Value
Collaboration Liabilities	inpha_CollaborationLiabilities	€ 40,415,000
Collaboration Liabilities	inpha_CollaborationLiabilities	46,686,000
Change In Working Capital	inpha_ChangeInWorkingCapital	58,660,000
Change In Working Capital	inpha_ChangeInWorkingCapital	68,543,000
Trade and other receivables	ifrs-full_TradeAndOtherReceivables	51,635,000
Trade and other receivables	ifrs-full_TradeAndOtherReceivables	48,241,000
Deferred income including contract liabilities	ifrs-full_DeferredIncomeIncludingContractLiabilities	37,913,000
Deferred income including contract liabilities	ifrs-full_DeferredIncomeIncludingContractLiabilities	43,973,000
Trade and other payables	ifrs-full_TradeAndOtherPayables	28,573,000
Trade and other payables	ifrs-full_TradeAndOtherPayables	€ 29,519,000